var title_f27_60_28608="Thumb spica cast 5";
var content_f27_60_28608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extend the underlayment to or just beyond the metacarpophalangeal joints such that there will be adequate padding at the rim of the cast once the underlayment is folded. Wrap the the forearm, hand, and thumb in webril or similar material. Try to make the wrap as smooth and evenly distributed as possible. Wrap the webril so each layer overlaps the previous layer by about three-fourths of its width. Additional material may be needed over bony prominences.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28608=[""].join("\n");
var outline_f27_60_28608=null;
var title_f27_60_28609="Quad sets PI";
var content_f27_60_28609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Quad sets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sit on the floor with the legs extended in front of the body. Place the hands behind the affected knee. Keep the leg straight and contract the quadriceps muscle (just above the knee), which should cause the knee cap to move towards the body. Hold for a count of 10 seconds. Release and rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28609=[""].join("\n");
var outline_f27_60_28609=null;
var title_f27_60_28610="Transverse temporal fracture";
var content_f27_60_28610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse temporal bone fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blunt trauma to the occipital or frontal region, resulting in a line of fracture through the cochlea&nbsp;(arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter C Weber, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28610=[""].join("\n");
var outline_f27_60_28610=null;
var title_f27_60_28611="Keratosis follicularis spinulosa decalvans";
var content_f27_60_28611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Keratosis follicularis spinulosa decalvans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cicatricial alopecia and follicular keratotic papules are features of keratosis follicularis spinulosa decalvans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28611=[""].join("\n");
var outline_f27_60_28611=null;
var title_f27_60_28612="JXG multiple scalp";
var content_f27_60_28612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple yellow-orange papules and plaques on the scalp of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28612=[""].join("\n");
var outline_f27_60_28612=null;
var title_f27_60_28613="Basic shoulder anatomy lateral view";
var content_f27_60_28613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Lateral view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 531px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28613=[""].join("\n");
var outline_f27_60_28613=null;
var title_f27_60_28614="Side by side closure enterotomy";
var content_f27_60_28614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Side-by-side gastrointestinal anastamosis (GIA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28614=[""].join("\n");
var outline_f27_60_28614=null;
var title_f27_60_28615="Timolol (ophthalmic): Drug information";
var content_f27_60_28615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Timolol (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=see_link\">",
"    see \"Timolol (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=see_link\">",
"    see \"Timolol (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betimol&reg;;",
"     </li>",
"     <li>",
"      Istalol&reg;;",
"     </li>",
"     <li>",
"      Timolol GFS;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg; in OcuDose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timop&reg;;",
"     </li>",
"     <li>",
"      Dom-Timolol;",
"     </li>",
"     <li>",
"      Mylan-Timolol;",
"     </li>",
"     <li>",
"      Novo-Timol;",
"     </li>",
"     <li>",
"      PMS-Timolol;",
"     </li>",
"     <li>",
"      Sandoz-Timolol;",
"     </li>",
"     <li>",
"      Tim-AK;",
"     </li>",
"     <li>",
"      Timolol Maleate-EX;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9600526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Solution:",
"     </i>",
"     Initial: 0.25% solution, instill 1 drop twice daily into affected eye(s); increase to 0.5% solution if response not adequate; decrease to 1 drop/day if controlled; do not exceed 1 drop twice daily of 0.5% solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Istalol&reg;:",
"     </i>",
"     Instill 1 drop (0.5% solution) once daily in the morning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gel-forming solution (Timolol GFS, Timoptic-XE&reg;):",
"     </i>",
"     Instill 1 drop (either 0.25% or 0.5%) once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9600260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=see_link\">",
"      see \"Timolol (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Solution:",
"     </i>",
"     Initial: Instill 1 drop (0.25% solution) into affected eye(s) twice daily; increase to 0.5% solution if response not adequate; decrease to 1 drop/day if controlled; do not exceed 1 drop twice daily of 0.5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gel-forming solution (Timolol GFS, Timoptic-XE&reg;):",
"     </i>",
"     Instill 1 drop (either 0.25% or 0.5% solution) once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel forming solution, ophthalmic, as maleate [strength expressed as base, drops]: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timolol GFS: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic-XE&reg;: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hemihydrate [strength expressed as base, drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betimol&reg;: 0.25% (5 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as maleate [strength expressed as base, drops]: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Istalol&reg;: 0.5% (2.5 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic&reg;: 0.25% (5 mL); 0.5% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as maleate [strength expressed as base, drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic&reg; in OcuDose&reg;: 0.25% (0.2 mL); 0.5% (0.2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution as maleate (preservative free), solution as hemihydrate",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9600264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer other topically-applied ophthalmic medications at least 10 minutes before Timoptic-XE&reg;; wash hands before use; invert closed bottle and shake once before use; remove cap carefully so that tip does not touch anything; hold bottle between thumb and index finger; use index finger of other hand to pull down the lower eyelid to form a pocket for the eye drop and tilt head back; place the dispenser tip close to the eye and gently squeeze the bottle to administer 1 drop; remove pressure after a single drop has been released;",
"     <b>",
"      do not allow the dispenser tip to touch the eye",
"     </b>",
"     ; replace cap and store bottle in an upright position in a clean area; do",
"     <b>",
"      not",
"     </b>",
"     enlarge hole of dispenser; do",
"     <b>",
"      not",
"     </b>",
"     wash tip with water, soap, or any other cleaner. Some solutions contain benzalkonium chloride; wait at least 10 minutes after instilling solution before inserting soft contact lenses.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9600190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of elevated intraocular pressure such as glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Timolol may be confused with atenolol, Tylenol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Timoptic&reg; may be confused with Betoptic S&reg;, Talacen, Viroptic&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bottle cap color change: Timoptic&reg;: Both the 0.25% and 0.5% strengths are now packaged in bottles with yellow caps; previously, the color of the cap on the product corresponded to different strengths.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betimol [U.S.] may be confused with Betanol brand name for metipranolol [Monaco]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9600211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Burning, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Frequency not defined:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, arrhythmia, bradycardia, cardiac arrest, cardiac failure, cerebral ischemia, cerebral vascular accident, edema, heart block, hypertension, hypotension, palpitation, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, depression, disorientation, dizziness, hallucinations, headache, insomnia, memory loss, nervousness, nightmares, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, pseudopemphigoid, psoriasiform rash, psoriasis exacerbation, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia masked, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence, retoperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenia gravis exacerbation, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blepharitis, blurred vision, cataract, choroidal detachment (following filtration surgery), conjunctival injection, conjunctivitis, corneal sensitivity decreased, cystoid macular edema, diplopia, dry eyes, foreign body sensation,  hyperemia, itching, keratitis, ocular discharge, ocular pain, ptosis, tearing, visual acuity decreased refractive changes, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, cold hands/feet, Peyronie's disease, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9600196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to timolol or any component of the formulation; sinus bradycardia; sinus node dysfunction; heart block greater than first degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure; bronchospastic disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9600208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Choroidal detachment: Beta-blockade and/or other suppressive therapy have been associated with choroidal detachment following filtration procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions, such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia. Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction). Multidose vials have been associated with development of bacterial keratitis; avoid contamination.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9600214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies; therefore, the manufacturer classifies timolol ophthalmic as pregnancy category C. Timolol crosses the placenta. Decreased fetal heart rate has been observed following maternal use of oral and ophthalmic timolol during pregnancy. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. If timolol is required for the treatment of glaucoma during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus. Also refer to the Timolol (Systemic) monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9600194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/ consider risk:benefit (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9600195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol is excreted into breast milk following ophthalmic administration. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Due to the potential for adverse events, nursing infants (especially those with cardiorespiratory problems) should be monitored. Also refer to the Timolol (Systemic) monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9600297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betimol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $73.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (10 mL): $155.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Istalol Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (2.5 mL): $111.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Timolol Maleate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (10 mL): $27.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (10 mL): $32.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Timoptic Ocudose Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (60): $331.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (60): $372.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Timoptic Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $130.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $141.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution get-forming",
"     </b>",
"     (Timolol Maleate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $49.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $58.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution get-forming",
"     </b>",
"     (Timoptic-XE Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $152.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $167.27",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timop (NZ);",
"     </li>",
"     <li>",
"      Blocanol (FI);",
"     </li>",
"     <li>",
"      Cusimolol (MY);",
"     </li>",
"     <li>",
"      Digaol (FR);",
"     </li>",
"     <li>",
"      Dispatim (DE);",
"     </li>",
"     <li>",
"      Elevex (PH);",
"     </li>",
"     <li>",
"      Geltim LP (FR);",
"     </li>",
"     <li>",
"      Glafemak (GR);",
"     </li>",
"     <li>",
"      Glauco (TH);",
"     </li>",
"     <li>",
"      Glauco Oph (HK, TH);",
"     </li>",
"     <li>",
"      Glaucosan (ZA);",
"     </li>",
"     <li>",
"      Glautimol (BR);",
"     </li>",
"     <li>",
"      Glucomol (IN);",
"     </li>",
"     <li>",
"      Imot Ofteno al (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Isotic Adretor (ID);",
"     </li>",
"     <li>",
"      Lolomit (CO);",
"     </li>",
"     <li>",
"      Noval (GR);",
"     </li>",
"     <li>",
"      Nyogel (AU, BE, FR, GB, IE, ZA);",
"     </li>",
"     <li>",
"      Nyogel LP (FR);",
"     </li>",
"     <li>",
"      Nyolol (BR, CH, CN, EE, FR, HK, IL, PT, PY, RU, SG, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Ocuper (PH);",
"     </li>",
"     <li>",
"      Ocupres (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ocupres-E (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Ofal (AR);",
"     </li>",
"     <li>",
"      Oftan (CZ, NO, PH);",
"     </li>",
"     <li>",
"      Oftan Timolol (HK);",
"     </li>",
"     <li>",
"      Ophtamolol (HK);",
"     </li>",
"     <li>",
"      Optamol (PH);",
"     </li>",
"     <li>",
"      Optimol (DK, MY, SE);",
"     </li>",
"     <li>",
"      Rysmon TG (KP);",
"     </li>",
"     <li>",
"      Temserin (GR);",
"     </li>",
"     <li>",
"      Tenopt (AU);",
"     </li>",
"     <li>",
"      Tilol (TW);",
"     </li>",
"     <li>",
"      Tiloptic (IL);",
"     </li>",
"     <li>",
"      Timabak (BE, HK);",
"     </li>",
"     <li>",
"      Timacor (FR);",
"     </li>",
"     <li>",
"      Timo-COMOD (KP);",
"     </li>",
"     <li>",
"      Timohexal (DE);",
"     </li>",
"     <li>",
"      Timol (TW);",
"     </li>",
"     <li>",
"      Timolast (TW);",
"     </li>",
"     <li>",
"      Timolux (NZ);",
"     </li>",
"     <li>",
"      Timoptic (AT, BG, CH, PE, PL);",
"     </li>",
"     <li>",
"      Timoptic-XE (KP);",
"     </li>",
"     <li>",
"      Timoptol (AU, BE, BF, BJ, CI, CL, CZ, DE, ET, FR, GB, GH, GM, GN, HK, IE, IT, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, PH, PK, PT, SC, SD, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Timoptol-XE (AU, CN, NZ, PE, SG, TW);",
"     </li>",
"     <li>",
"      Timosan (EE, FI, SE);",
"     </li>",
"     <li>",
"      Tiof (EC);",
"     </li>",
"     <li>",
"      Tiopex (GB);",
"     </li>",
"     <li>",
"      V-Optic (IL);",
"     </li>",
"     <li>",
"      Yesan (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Intraocular pressure reduction: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Timolol is measurable in the serum following ophthalmic use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/60/28615/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coppens G, Stalmans I, Zeyen T, et al, \"The Safety and Efficacy of Glaucoma Medication in the Pediatric Population,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 2009, 46(1):12-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/60/28615/abstract-text/19213271/pubmed\" id=\"19213271\" target=\"_blank\">",
"        19213271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mundorf TK, Ogawa T, Naka H, et al, &ldquo;A 12-Month, Multicenter, Randomized, Double-Masked, Parallel-Group Comparison of Timolol-LA Once Daily and Timolol Maleate Ophthalmic Solution Twice Daily in the Treatment of Adults With Glaucoma or Ocular Hypertension,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2004, 26(4):541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/60/28615/abstract-text/15189751/pubmed\" id=\"15189751\" target=\"_blank\">",
"        15189751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plager DA, Whitson JT, Netland PA, et al, \"Betaxolol Hydrochloride Ophthalmic Suspension 0.25% and Timolol Gel-Forming Solution 0.25% and 0.5% in Pediatric Glaucoma: A Randomized Clinical Trial,\"",
"      <i>",
"       J AAPOS",
"      </i>",
"      , 2009, 13(4):384-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/60/28615/abstract-text/19683191/pubmed\" id=\"19683191\" target=\"_blank\">",
"        19683191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagenvoort AM, van Vugt JM, Sobotka M, et al, &ldquo;Topical Timolol Therapy in Pregnancy: Is It Safe for the Fetus?&rdquo;",
"      <i>",
"       Teratology",
"      </i>",
"      , 1998, 58(6):258-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/60/28615/abstract-text/9894675/pubmed\" id=\"9894675\" target=\"_blank\">",
"        9894675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9942 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28615=[""].join("\n");
var outline_f27_60_28615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600526\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600260\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600262\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600295\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600189\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600264\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600190\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600171\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600211\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600196\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600208\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600214\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600215\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600191\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600192\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600194\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600195\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600297\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962008\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600228\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600230\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25014?source=related_link\">",
"      Timolol (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=related_link\">",
"      Timolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_60_28616="Clinical manifestations and diagnosis of chronic pancreatitis in children";
var content_f27_60_28616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic pancreatitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Mohamad Miqdady, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Seiji Kitagawa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28616/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28616/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28616/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/60/28616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis is a progressive inflammatory disease of the pancreas. It is characterized by irreversible structural changes that result in irreversible exocrine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The structural changes include irregular sclerotic and diffuse or focal destruction, acinar cell loss, islet cell loss, inflammatory cell filtrate, and pancreatic duct abnormalities. Intraductal obstruction may be caused by protein-plugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calculi.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the clinical manifestations, diagnosis, and prognosis in children with chronic pancreatitis. Discussions of specific etiologies of chronic pancreatitis in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42727?source=see_link\">",
"     \"Causes of chronic pancreatitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of chronic pancreatitis are similar regardless of the etiology. The age of onset, rate of disease progression, and prognosis depend upon the specific etiology and severity of the underlying condition or process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42727?source=see_link\">",
"     \"Causes of chronic pancreatitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients present with recurrent episodes of acute pancreatitis. Others may present with abdominal pain of insidious onset. Another group of patients may present with malabsorption or obstructive jaundice caused by obstruction of the common bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/4\">",
"     4",
"    </a>",
"    ]. Less commonly, patients may be asymptomatic or present only after signs of pancreatic failure (eg, malabsorption, diabetes), which occurs late in the course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/1,3,5,6\">",
"     1,3,5,6",
"    </a>",
"    ]. These presentations are discussed in greater detail below.",
"   </p>",
"   <p>",
"    Chronic pancreatitis should be considered in the differential diagnosis of children with growth failure, particularly those with a weight deficit and malnutrition. The examination is often normal, but may include epigastric or upper abdominal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/3\">",
"     3",
"    </a>",
"    ]. An epigastric mass may be palpated if the patient has developed a pseudocyst. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain is the cardinal feature of chronic pancreatitis. However, the pain pattern varies among patients and tends to fluctuate during the course of the disease. In some patients, with the loss of pancreatic tissue and fibrosis, the pain eventually improves.",
"   </p>",
"   <p>",
"    The pain typically is epigastric, often radiates to the back, is often associated with nausea and vomiting, and may be relieved by sitting upright or leaning forward. The pain often is worse 15 to 30 minutes after eating, especially if fatty food is consumed. Early in the course of chronic pancreatitis, the pain may occur in discrete attacks; as the condition progresses, the pain tends to become more continuous. There is some evidence that patients suffering from chronic pancreatitis may have pronounced generalized hyperalgesia, which is more prominent in males [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal pain is a frequent complaint in children, and may be caused by a variety of physiological and functional disorders. Functional abdominal pain is the most common cause of recurrent abdominal pain in children. However, it is helpful to remember that functional abdominal pain is not related to meals, is rarely associated with vomiting, and the child's growth usually is normal. The clinician must attempt to distinguish between possible causes on the basis of the clinical pattern of symptoms, supported by carefully selected laboratory testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"     \"Causes of acute abdominal pain in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe pancreatic exocrine dysfunction cannot properly digest complex foods or absorb digestive breakdown products. Nevertheless, clinically significant protein and fat deficiencies do not occur until more than 70 to 90 percent of pancreatic function is lost [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/5\">",
"     5",
"    </a>",
"    ]. In a national series of 200 patients with hereditary pancreatitis in France, exocrine pancreatic insufficiency eventually developed in 34 percent, and presented at a mean age of 29 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/8\">",
"     8",
"    </a>",
"    ]. Protein maldigestion typically occurs earlier than fat maldigestion when measured in stool, and clinically important nutrient deficiencies may occur in the absence of steatorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, we suggest that dosing of enzyme therapy be based on the results of laboratory tests for fat malabsorption using stool or breath (eg, breath (13)C-mixed triglyceride), rather than on clinical symptoms of steatorrhea.",
"   </p>",
"   <p>",
"    The clinical manifestations of fat malabsorption include loose, greasy, foul smelling stools that are difficult to flush. Malabsorption of the fat soluble vitamins (A, D, E, K) and vitamin B12 also may occur, although clinically symptomatic vitamin deficiency is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose intolerance occurs with some frequency in chronic pancreatitis, but overt diabetes mellitus usually occurs only late in the course of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In the national series of 200 patients with hereditary pancreatitis in France, diabetes mellitus eventually developed in 26 percent, and presented at a mean age of 38 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic calcifying disease, particularly those who develop early calcifications, may develop diabetes more frequently than those with chronic noncalcifying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/13\">",
"     13",
"    </a>",
"    ]. Diabetes also is more likely to occur in patients with a family history of type 1 or type 2 diabetes; this observation suggests a role for an underlying decrease in pancreatic reserve or in insulin responsiveness.",
"   </p>",
"   <p>",
"    Diabetes that develops in patients with chronic pancreatitis usually is insulin-requiring. However, it is different from typical type 1 diabetes in that the pancreatic alpha cells, which produce glucagon, are also affected. As a result, there is an increased risk of hypoglycemia, both treatment related and spontaneous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the manifestations described above, chronic pancreatitis may manifest with signs or symptoms related to various complications. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bile duct and duodenal obstruction, which may cause abdominal pain and abnormal liver function tests or postprandial pain and early satiety, respectively",
"     </li>",
"     <li>",
"      Pseudocysts, which are usually asymptomatic, but may be associated with fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epigastric mass. Depending upon the location and extent of the fluid collection, pseudocysts may cause a variety of problems, including each of the complications listed here",
"     </li>",
"     <li>",
"      Pancreatic ascites and pleural effusion, which may cause abdominal distension, early satiety,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shortness of breath",
"     </li>",
"     <li>",
"      Splenic vein thrombosis, which may result in gastric varices",
"     </li>",
"     <li>",
"      Pseudoaneurysms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic pancreatitis is relatively straightforward and can be suspected clinically in patients who present with acute pancreatitis followed by recurring attacks of pain. Diagnosis is more challenging in those with few or mild symptoms. In such patients, the diagnosis depends upon the strength of clinical features, combined with functional and morphologic evaluation of the pancreas, as described below.",
"   </p>",
"   <p>",
"    In patients with recurrent upper abdominal pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatic insufficiency, the diagnosis of chronic pancreatitis is confirmed if there are calcifications within the pancreas on abdominal plain films or CT scans, increased diameter of the pancreatic duct on ultrasonography, abnormal pancreatogram revealing beading of the main pancreatic duct or ectatic side branches, or direct or indirect evidence of pancreatic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pancreatitis should be considered in children with one or more of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent epigastric abdominal pain, with or without vomiting, if other causes are unlikely",
"     </li>",
"     <li>",
"      Family history of chronic pancreatitis",
"     </li>",
"     <li>",
"      Growth failure, particularly those with a weight deficit and malnutrition caused by maldigestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis can be confirmed with various laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging tests. The choice and order of diagnostic tests depends upon the age, presence of underlying conditions, and to a large extent, the availability of specialized imaging studies. Laboratory tests, if abnormal, are helpful, but may lack specificity (ie, pancreatic insufficiency can occur in a variety of disorders). Imaging can help to confirm the diagnosis in these cases as well as in patients in whom the laboratory evaluation is normal. Advantages and disadvantages of individual laboratory and imaging tests are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general approach for patients in whom the clinical evaluation is consistent with chronic pancreatitis is to begin with routine tests that are readily available and easy to perform, and proceed to more specialized testing as needed.",
"   </p>",
"   <p>",
"    We perform routine laboratory tests in most patients, and all patients who complain of pain. These include complete blood count, electrolytes, serum glucose, liver function tests, and serum pancreatic enzymes. We measure fat soluble vitamins if serum calcium is low. We assess vitamin K adequacy indirectly by measuring prothrombin time (PT) and vitamin D by measuring 25(OH)-vitamin D levels. For vitamins A and E, direct measurements of serum levels are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link\">",
"     \"Overview of vitamin K\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also obtain a spot stool sample for Sudan III stain for fecal fat and measurement of fecal elastase-1. These tests have low accuracy for steatorrhea and are subject to user interpretation. However, they are reasonable first steps in the assessment for steatorrhea because they are easier to obtain than a 72-hour stool collection. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Stool fat'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Pancreatic function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, we obtain genetic testing for hereditary pancreatitis in all patients in whom we suspect chronic pancreatitis, whether or not pancreatic function is abnormal. Indications for genetic testing vary depending on whether the patient is being evaluated because of clinical symptoms (diagnostic testing), or because of a family history of chronic pancreatitis (predictive testing). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link\">",
"     \"Hereditary pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use imaging tests to confirm the diagnosis in patients with abnormal stool studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic testing, as well as to make the diagnosis in patients in whom the laboratory evaluation is normal but in whom the clinical symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history suggest the disease. Normal results of indirect tests of pancreatic function (ie, testing the stools) do not exclude the diagnosis of chronic pancreatitis.",
"   </p>",
"   <p>",
"    We usually begin the radiologic evaluation with plain radiographs and transabdominal ultrasonography. These tests are universally available, and in some cases may preclude the need for computed tomography (CT) or pancreatography. CT provides better visualization than ultrasonography, particularly in overweight children, and is more available and less invasive than pancreatography or abdominal ultrasonography. We proceed to ERCP or MRCP, only as necessary. These tests, like endoscopic ultrasonography, are not widely available for children. In most centers,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    -enhanced MRCP has replaced ERCP for diagnostic testing. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the tests described below do not become abnormal until advanced pancreatic disease is present. Thus, they are not usually helpful in early mild or moderate chronic pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Routine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood count, electrolytes, and liver function tests usually are normal in patients with chronic pancreatitis. Exceptions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum glucose in patients with diabetes mellitus or insulin resistance",
"     </li>",
"     <li>",
"      Elevation of serum bilirubin, alkaline phosphatase, and liver enzymes in patients with concomitant liver disease or bile duct obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other abnormalities may include low concentrations of carotene, fat-soluble vitamins, and essential fatty acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum pancreatic enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of pancreatic enzymes usually is not helpful in making the diagnosis of chronic pancreatitis, particularly early in the course or if pancreatitis is of mild to moderate severity. Serum concentrations of amylase, lipase, and protease frequently are normal in patients with chronic pancreatitis, even during an attack of pain. Nonetheless, we suggest measuring serum amylase and lipase in all patients in whom chronic pancreatitis is suspected on the basis of clinical symptoms. Abnormal results support the diagnosis of chronic pancreatitis, and should prompt further evaluation. Normal results for amylase and lipase do not exclude the diagnosis of chronic pancreatitis. The serum concentration of other pancreatic enzymes, such as trypsinogen and isoamylase, may be reduced in patients with chronic pancreatitis, but usually only in those with advanced disease. As an example, trypsinogen levels often are elevated in young children who are in early stages of cystic fibrosis affecting the pancreas; later in the course of the disease, trypsinogen levels fall, indicating loss of pancreatic function.",
"   </p>",
"   <p>",
"    Measurement of serum amylase, lipase,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protease also may be helpful when evaluating patients for complications such as pseudocysts or pancreatic ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pancreatic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are various direct and indirect measures of pancreatic function, which, in conjunction with clinical and morphologic findings, can assist in the diagnosis of chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/6\">",
"     6",
"    </a>",
"    ]. Information from pancreatic function tests must be supplemented with clinical and morphologic information because pancreatic function tests do not distinguish chronic pancreatitis from disorders of pancreatic insufficiency without pancreatitis (eg, Shwachman-Diamond syndrome), or from nonpancreatic diseases (eg, mucosal small bowel diseases). In addition, normal pancreatic function test results do not exclude chronic pancreatitis, particularly when it is of mild or moderate severity.",
"   </p>",
"   <p>",
"    Direct measures of pancreatic function are invasive and involve assays of pancreatic secretions that are obtained directly after stimulation with secretagogues (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    , cholecystokinin). Pancreatic secretions are collected at endoscopy or through a duodenal tube and assayed for bicarbonate, amylase, trypsin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipase depending upon the stimulus that was used. These tests have fallen out of favor because they are not well-standardized in children, are invasive, expensive, and cumbersome to perform. In addition the availability of advanced radiologic studies often makes them unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=see_link\">",
"     \"Pancreatic exocrine function tests\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Indirect tests, which are noninvasive, less expensive and less cumbersome than direct tests, are more practical for use in routine clinical practice. However, they are less sensitive and specific than direct tests, particularly in patients with mild to moderate disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/14\">",
"     14",
"    </a>",
"    ]. Indirect tests include measurement of fecal elastase-1 or chymotrypsin.",
"   </p>",
"   <p>",
"    Indirect tests of pancreatic function include measurement of fecal elastase-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chymotrypsin; the stool content of these enzyme is reduced in patients with pancreatic insufficiency. The diagnostic accuracy of these tests is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=see_link\">",
"     \"Pancreatic exocrine function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of fecal elastase-1 is more sensitive than fecal chymotrypsin, particularly in the early phases of pancreatic insufficiency. In addition, because it is specific for the human enzyme, its values are independent of pancreatic enzyme replacement therapy.",
"     </li>",
"     <li>",
"      Measurement of stool chymotrypsin may be affected by the administration of pancreatic enzyme replacement, thus enzyme replacement should be discontinued for at least three days before this test is performed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, these are tests for pancreatic insufficiency, and positive results do not necessarily indicate chronic pancreatitis. Decreased fecal elastase-1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chymotrypsin also occur in children with other causes of diarrhea, including villous atrophy (as in celiac disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/15-17\">",
"     15-17",
"    </a>",
"    ] and bacterial or viral gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Other causes of exocrine pancreatic insufficiency in children include pancreatic agenesis, hypoplasia or resection, cystic fibrosis, Shwachman-Diamond syndrome, isolated enzyme deficiencies, malnutrition, primary sclerosing cholangitis, and Alagille syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stool fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests can be used to detect fat malabsorption (steatorrhea). The gold standard for diagnosis of steatorrhea is quantitative estimation of stool fat, usually performed over 72 hours, while the patient eats a diet containing 100 g of fat per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'Tests for fat malabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because 72 hour stool collection is cumbersome, qualitative tests are also used to detect steatorrhea. These include the Sudan III stain and acid steatocrit, a rapid gravimetric method. The sensitivity and reliability of the Sudan III test is limited by variability in its performance and interpretation. The sensitivity and specificity of the acid steatocrit approach that of the 72 hour quantitative collection, even when performed on a spot sample. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'Tests for fat malabsorption'",
"    </a>",
"    .) However, the acid steatocrit may not be routinely available in many clinical settings.",
"   </p>",
"   <p>",
"    Quantitative and qualitative fecal fat tests are most accurate in patients with severe chronic pancreatitis and malabsorption. They cannot and should not be used to diagnose mild to moderate chronic pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical indications for genetic testing for hereditary pancreatitis include unexplained pancreatitis in a child, or unexplained recurrent acute or chronic pancreatitis in older individuals. Mutations in the following genes may be associated with chronic pancreatitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PRSS1",
"      </strong>",
"      &ndash; Mutations in the gene encoding serine protease 1 (PRSS1, or cationic trypsinogen) are identified in up to 80 percent of families with hereditary pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H3#H3\">",
"       \"Hereditary pancreatitis\", section on 'PRSS1'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       SPINK1",
"      </strong>",
"      &ndash; There is a weaker association between chronic pancreatis and mutations in the",
"      <strong>",
"       s",
"      </strong>",
"      erine",
"      <strong>",
"       p",
"      </strong>",
"      rotease",
"      <strong>",
"       in",
"      </strong>",
"      hibitor",
"      <strong>",
"       K",
"      </strong>",
"      azal type",
"      <strong>",
"       1",
"      </strong>",
"      gene (SPINK1). SPINK1 mutations are fairly common in the general population (2 percent of healthy individuals carry a \"high risk\" mutation) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/19\">",
"       19",
"      </a>",
"      ], but less than 1 percent of carriers develop pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/20\">",
"       20",
"      </a>",
"      ]. Therefore, the SPINK 1 mutations probably act as disease modifiers, lowering the threshold for pancreatitis caused by other genetic or environmental factors (eg, a second gene mutation, alcohol, or other insult). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H2#H2\">",
"       \"Hereditary pancreatitis\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       CFTR",
"      </strong>",
"      &ndash; Mutations in the cystic fibrosis transmembrane regulator gene (CFTR) can cause pancreatitis with or without associated manifestations of cystic fibrosis. Chronic pancreatitis may occur in the setting of homozygous mutations (typical cystic fibrosis), compound heterozygosity (atypical cystic fibrosis), or occasionally with the carrier state. In the latter condition, environmental or other modifiers likely contribute to the pathogenesis of the disease. Most diagnostic laboratories in the United States screen for 20 to 30 of the most common mutations causing cystic fibrosis in the US population. These panels may not capture less common mutations of CFTR, and may not reflect common mutations in other populations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H22#H22\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Molecular diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H16024358#H16024358\">",
"       \"Hereditary pancreatitis\", section on 'CFTR'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing is available for each of these genes. The results of genetic testing are highly accurate. However, because clinical disease is strongly influenced by genetic or environmental modifiers, the results of genetic testing alone are not useful to predict prognosis except in specific situations. The indications for genetic testing in patients with chronic pancreatitis and in asymptomatic patients with a family history of hereditary pancreatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary pancreatitis\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are the mainstay of diagnosis of chronic pancreatitis. We typically begin with abdominal plain films and transabdominal ultrasonography, and then proceed to endoscopic ultrasonography or CT scan, then to endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographic examination of the abdomen may reveal focal or diffuse calcification of the pancreas, which confirms the diagnosis of chronic calcific pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ultrasonography (US)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal ultrasonography can be valuable in diagnosis and monitoring children with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Findings associated with chronic pancreatitis include increased diameter of the pancreatic duct and little or no duct dilation in response to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Endoscopic US",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) appears to be a promising tool for evaluation of pancreatobiliary disorders in children. In a small prospective study, EUS was performed in 14 children who were scheduled to undergo ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/23\">",
"     23",
"    </a>",
"    ]. EUS was successful in all patients, helpful in establishing a diagnosis of chronic pancreatitis in three patients and pancreatic divisum in one patient, and precluded the need for ERCP in nine. The ability to perform EUS-guided fine needle aspiration (FNA) enhances the usefulness of this test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Abdominal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal CT scan is fairly sensitive in identifying moderate to severe chronic pancreatitis. Typical findings in chronic pancreatitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcification within the pancreatic ducts or parenchyma",
"     </li>",
"     <li>",
"      Dilatation of the main pancreatic ducts",
"     </li>",
"     <li>",
"      Pancreatic atrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other abnormalities that may be seen include pancreatic enlargement, cystic lesions, and fatty replacement (particularly in cystic fibrosis and Shwachman-Diamond syndrome). CT is more sensitive than is ultrasound in demonstrating the extent of disease and permits characterization of the tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ERCP and MRCP are acceptable approaches for evaluating a child with chronic pancreatitis. The choice depends on the expertise and preference available at the institution, and whether therapeutic intervention is anticipated. Some experts suggest MRCP prior to consideration of ERCP for most patients with chronic or recurrent pancreatitis, because MRCP is less invasive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24088?source=see_link&amp;anchor=H5495726#H5495726\">",
"     \"ERCP for pancreatic disease in children\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic retrograde cholangiopancreatography (ERCP) has been used extensively in the diagnosis and treatment of adults and children with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. We now prefer MRCP for the diagnosis of chronic pancreatitis in patients with suggestive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/27\">",
"     27",
"    </a>",
"    ]. However, ERCP may be useful for therapeutic interventions, such as sphincterotomy, stent placement, and stone removal, and can also identify structural abnormalities of the pancreatic and biliary ducts. Early in the course of chronic pancreatitis, findings are confined to smaller ducts. With progression of the disease, the main pancreatic duct appears to be beaded in areas of obstruction secondary to stricture formation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64898 \" href=\"UTD.htm?9/33/9759\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H25\">",
"     'MRCP'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24088?source=see_link\">",
"     \"ERCP for pancreatic disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     MRCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance cholangiopancreatography (MRCP) can demonstrate the pancreatobiliary tree (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72655 \" href=\"UTD.htm?24/36/25152\">",
"     image 2",
"    </a>",
"    ). Its advantages compared to ERCP are that it is noninvasive and avoids the use of ionizing radiation. Newer generation tests using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     secretin",
"    </a>",
"    enhancement of MRCP may be as effective as ERCP for detecting ductal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/28\">",
"     28",
"    </a>",
"    ]. MRCP can evaluate the pancreatic parenchyma and visualize regions above an obstruction, and has lower risks than ERCP. Therefore, MRCP may be preferable to ERCP for the evaluation of chronic pancreatitis, except when biliary pancreatitis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link&amp;anchor=H11#H11\">",
"     \"Magnetic resonance cholangiopancreatography\", section on 'Pancreatitis and pancreatic cancer'",
"    </a>",
"    .) However, the diagnostic value of MRCP may vary between centers and by the age of the child, and few studies have directly compared MRCP to ERCP in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28616/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis is a progressive inflammatory disease of the pancreas. It is characterized by irreversible structural changes that result in irreversible exocrine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine pancreatic insufficiency. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis should be considered in the differential diagnosis of children with growth failure, particularly those with a weight deficit and malnutrition due to maldigestion. The examination is often normal, but may include epigastric or upper abdominal tenderness. Other manifestations include protein and fat malabsorption, diabetes, abnormal liver function tests, postprandial pain, early satiety, and jaundice. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the appropriate clinical setting, the diagnosis of chronic pancreatitis may be confirmed by various laboratory and radiologic tests. These include: calcifications within the pancreas on abdominal plain films or CT scans, increased diameter of the pancreatic duct on ultrasonography, abnormal pancreatogram revealing beading of the main pancreatic duct or ectatic side branches, or direct or indirect evidence of pancreatic insufficiency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice and order of the diagnostic evaluation depends upon the patient's age, presence of underlying conditions, and the availability of specialized imaging studies. We suggest beginning with routine tests that are readily available and easy to perform, and proceeding to more specialized testing as needed. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following initial evaluation in all patients in whom chronic pancreatitis is suspected on the basis of clinical symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count, electrolytes, liver function tests, and pancreatic enzymes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Routine tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indirect tests of pancreatic function: Spot stool sample for Sudan III stain and fecal elastase-1 assay. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stool fat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Pancreatic function'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal results of these tests support the diagnosis of chronic pancreatitis in a patient with suggestive clinical symptoms; such patients should be further evaluated with genetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      imaging tests.",
"     </li>",
"     <li>",
"      Normal results these tests do not necessarily exclude the diagnosis of chronic pancreatitis; patients with normal results but strongly suggestive clinical symptoms or family history of hereditary pancreatitis also should have further evaluation with genetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      imaging tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Genetic tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical indications for genetic testing for hereditary pancreatitis include unexplained pancreatitis in a child, or unexplained recurrent acute or chronic pancreatitis in older individuals. Mutations in serine protease 1 gene (PRSS1, encoding cationic trypsinogen) are strongly associated with hereditary pancreatitis; heterozygous mutations of PRSS1 are present in about 75 percent of individuals with hereditary pancreatitis. Mutations in serine protease inhibitor Kazal type 1 gene (SPINK1) or cystic fibrosis transmembrane conductance regulator (CFTR) should also be considered in patients presenting with chronic pancreatitis. However, because clinical disease is strongly influenced by genetic or environmental modifiers, the results of genetic testing alone are not useful to predict prognosis except in specific situations. Indications for genetic testing are discussed in a separate topic review. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Genetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary pancreatitis\", section on 'Genetic testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We use imaging tests to confirm the diagnosis in patients with abnormal stool studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic testing. Imaging also may be used for patients in whom the laboratory evaluation is normal but in whom the clinical symptoms suggest the possibility of chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest beginning the radiologic evaluation with plain radiographs and transabdominal ultrasonography. The diagnosis of chronic calcific pancreatitis is confirmed by the finding of diffuse calcification of the pancreas on plain radiographs or by increased diameter of the pancreatic duct on ultrasonography. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Plain films'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Ultrasonography (US)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is equivocal, we suggest abdominal computed tomography (CT). Typical CT findings of chronic pancreatitis include calcification within the pancreatic ducts or parenchyma, dilation of the main pancreatic ducts, pancreatic atrophy or enlargement, cystic lesions and fatty replacement. Alternatively, the pancreas can be imaged with MRCP rather than CT, if MRCP is readily available. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Abdominal CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Finally, we suggest proceeding to magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) as necessary. MRCP may reveal dilation of the main pancreatic duct (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72655 \" href=\"UTD.htm?24/36/25152\">",
"       image 2",
"      </a>",
"      ). ERCP findings of chronic pancreatitis include beading of the main pancreatic duct secondary to stricture formation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64898 \" href=\"UTD.htm?9/33/9759\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pancreatography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Owyang C. Chronic pancreatitis. In: Textbook of Gastroenterology, 4th, Yamada T (Ed), Lippincott, Williams and Wilkins, Philadelphia 2003. p.2061.",
"    </li>",
"    <li>",
"     Sarner, M. Pancreatitis definition and classification. In: Go, VL, DiMagno, EP, Gardner, JD, Lebenthal, E, et al (Eds), The Pancreas: Pathology and Disease, 2nd ed, Raven, New York, 1993. p.575.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/3\">",
"      Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med 1995; 332:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/4\">",
"      Wheatley MJ, Coran AG. Obstructive jaundice secondary to chronic pancreatitis in children: report of two cases and review of the literature. Surgery 1988; 104:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/5\">",
"      DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme ouputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973; 288:813.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcomb, DC. Lowe, ME. Acute and chronic pancreatitis. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker, WA, Goulet, O, Kleinman, RE, et al (Eds), BC Decker, Ontario, 2004. p. 1584.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/7\">",
"      Buscher HC, Wilder-Smith OH, van Goor H. Chronic pancreatitis patients show hyperalgesia of central origin: a pilot study. Eur J Pain 2006; 10:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/8\">",
"      Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut 2009; 58:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/9\">",
"      Dom&iacute;nguez-Mu&ntilde;oz JE, Iglesias-Garc&iacute;a J, Vilari&ntilde;o-Insua M, Iglesias-Rey M. 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007; 5:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/10\">",
"      Toskes PP, Hansell J, Cerda J, Deren JJ. Vitamin B 12 malabsorption in chronic pancreatic insufficiency. N Engl J Med 1971; 284:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/11\">",
"      Sjoberg RJ, Kidd GS. Pancreatic diabetes mellitus. Diabetes Care 1989; 12:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/12\">",
"      Lankisch PG, L&ouml;hr-Happe A, Otto J, Creutzfeldt W. Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion 1993; 54:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/13\">",
"      Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000; 119:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/14\">",
"      Walkowiak J, Nousia-Arvanitakis S, Henker J, et al. Indirect pancreatic function tests in children. J Pediatr Gastroenterol Nutr 2005; 40:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/15\">",
"      David-Henriau L, Bui S, Molinari I, et al. [Fecal elastase-1: a useful test in pediatric practice]. Arch Pediatr 2005; 12:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/16\">",
"      Carroccio A, Iacono G, Ippolito S, et al. Usefulness of faecal elastase-1 assay in monitoring pancreatic function in childhood coeliac disease. Ital J Gastroenterol Hepatol 1998; 30:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/17\">",
"      Walkowiak J, Herzig KH. Fecal elastase-1 is decreased in villous atrophy regardless of the underlying disease. Eur J Clin Invest 2001; 31:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/18\">",
"      Salvatore S, Finazzi S, Barassi A, et al. Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr 2003; 36:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/19\">",
"      Fink EN, Kant JA, Whitcomb DC. Genetic counseling for nonsyndromic pancreatitis. Gastroenterol Clin North Am 2007; 36:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/20\">",
"      Pf&uuml;tzer RH, Barmada MM, Brunskill AP, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/21\">",
"      Chao HC, Lin SJ, Kong MS, Luo CC. Sonographic evaluation of the pancreatic duct in normal children and children with pancreatitis. J Ultrasound Med 2000; 19:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/22\">",
"      Glaser J, Stienecker K. Ultrasound secretin test in patients with pancreas divisum--an aid in the diagnosis of papillary or dorsal duct stenosis? Z Gastroenterol 1999; 37:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/23\">",
"      Varadarajulu S, Wilcox CM, Eloubeidi MA. Impact of EUS in the evaluation of pancreaticobiliary disorders in children. Gastrointest Endosc 2005; 62:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/24\">",
"      Vaughn DD, Jabra AA, Fishman EK. Pancreatic disease in children and young adults: evaluation with CT. Radiographics 1998; 18:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/25\">",
"      Werlin SL. Endoscopic retrograde cholangiopancreatography in children. Gastrointest Endosc Clin N Am 1994; 4:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/26\">",
"      Brown CW, Werlin SL, Geenen JE, Schmalz M. The diagnostic and therapeutic role of endoscopic retrograde cholangiopancreatography in children. J Pediatr Gastroenterol Nutr 1993; 17:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/27\">",
"      Cohen S, Bacon BR, Berlin JA, et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc 2002; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/28\">",
"      Darge K, Anupindi S. Pancreatitis and the role of US, MRCP and ERCP. Pediatr Radiol 2009; 39 Suppl 2:S153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/29\">",
"      Tipnis NA, Dua KS, Werlin SL. A retrospective assessment of magnetic resonance cholangiopancreatography in children. J Pediatr Gastroenterol Nutr 2008; 46:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/30\">",
"      Fitoz S, Erden A, Boruban S. Magnetic resonance cholangiopancreatography of biliary system abnormalities in children. Clin Imaging 2007; 31:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/31\">",
"      Arcement CM, Meza MP, Arumanla S, Towbin RB. MRCP in the evaluation of pancreaticobiliary disease in children. Pediatr Radiol 2001; 31:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28616/abstract/32\">",
"      Delaney L, Applegate KE, Karmazyn B, et al. MR cholangiopancreatography in children: feasibility, safety, and initial experience. Pediatr Radiol 2008; 38:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5896 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28616=[""].join("\n");
var outline_f27_60_28616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Routine tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum pancreatic enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pancreatic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stool fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Plain films",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ultrasonography (US)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Endoscopic US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pancreatography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - MRCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Genetic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5896|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/33/9759\" title=\"diagnostic image 1\">",
"      Chronic pancreatitis ERCP child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/36/25152\" title=\"diagnostic image 2\">",
"      Chronic pancreatitis MRCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42727?source=related_link\">",
"      Causes of chronic pancreatitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24088?source=related_link\">",
"      ERCP for pancreatic disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=related_link\">",
"      Hereditary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=related_link\">",
"      Pancreatic exocrine function tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_60_28617="Clinical manifestations of hereditary hemochromatosis";
var content_f27_60_28617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28617/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28617/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/60/28617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis is an autosomal recessive disorder in which mutations in the HFE gene cause increased intestinal iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H9#H9\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'The HFE protein'",
"    </a>",
"    .) The clinical manifestations of this disorder, and of other forms of iron overload, are related to excessive iron deposition in tissues, especially the liver, heart, pancreas, and pituitary.",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of hereditary hemochromatosis (HH) will be reviewed here. The pathophysiology and diagnosis of iron overload, causes of iron overload other than HH, and treatment of HH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These topics are also discussed in an official 2011 guideline issued by the American Association for the Study of Liver Diseases. The guideline for the diagnosis and management of hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AASLD guidelines, can be accessed through the AASLD website at:",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis was previously thought to be a rare disorder to be considered only when the patient had an unusual manifestation such as \"bronze diabetes.\" However, once it was appreciated that HH was transmitted as an autosomal recessive trait associated with the HLA-A locus on the short arm of chromosome 6, accurate family analyses could be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/2\">",
"     2",
"    </a>",
"    ]. These studies revealed that a transferrin saturation (serum iron concentration &divide; total iron binding capacity) over 60 percent in men and over 50 percent in women identified the presence of an abnormality in iron metabolism (heterozygotes and homozygotes) with approximately 95 percent accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Population screening has shown that the frequency of heterozygotes is about 10 percent in Caucasian populations in the United States and western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ], with a frequency of about 5 per 1000 (0.5 percent) for the homozygous state [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The prevalence was higher (about 1 percent) in a screening study which assumed that 60 percent of patients with an elevated transferrin saturation but normal serum ferritin had early HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/5\">",
"     5",
"    </a>",
"    ]. It is now known that the vast majority of patients so diagnosed were homozygous for the C282Y mutation of the HFE protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'The HFE gene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gene defects other than HFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the vast majority of patients with clinically diagnosed HH have mutations of the HFE gene, other gene defects leading to HH have been described (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 1",
"    </a>",
"    ). This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H13#H13\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Other gene defects leading to iron overload or high ferritin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Juvenile hemochromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon form of HH occurs in childhood and is termed juvenile hemochromatosis, also an autosomal recessive disorder. It is earlier in onset and more severe than typical HH and appears genetically distinct, not being due to the abnormal HFE gene that is responsible for HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The disease has been most commonly reported in Italy. A discussion of the genetic abnormality in this disorder can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H14#H14\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Juvenile hemochromatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of six female and two male patients from five unrelated Greek families with juvenile hemochromatosis, symptoms and signs began between the ages of 19 and 39, and included mildly deforming arthritis, especially of the second and third metacarpophalangeal joints, hypogonadotropic hypogonadism, elevated liver enzymes with liver fibrosis or cirrhosis, and reduced bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/10\">",
"     10",
"    </a>",
"    ]. The arthritis was progressive independent of treatment with phlebotomy.",
"   </p>",
"   <p>",
"    However, in general, affected individuals with juvenile hemochromatosis are more likely to present with cardiomyopathy, reduced glucose tolerance, and hypogonadism, rather than severe liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     African Americans",
"    </span>",
"    &nbsp;&mdash;&nbsp;A disorder of iron overload with the clinical and liver biopsy features of HH has been described in four African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/12\">",
"     12",
"    </a>",
"    ]. The pathophysiology of this disorder was not determined; the cellular and tissue distribution of iron was different from that in typical HLA-linked HH. It has been suggested that a gene affecting iron metabolism that is distinct from HFE may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/13\">",
"     13",
"    </a>",
"    ]. Whether this gene is related to the one predisposing to African iron overload is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H10#H10\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'African iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, absorption of heme and non-heme iron is inversely correlated with iron stores, as reflected by the serum ferritin concentration. Iron is normally lost in sweat, shed skin cells, and the gastrointestinal tract at a rate of approximately 1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Premenopausal adult women lose an additional 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    because of menses. These losses are usually balanced by the absorption of 10 percent of the 10 to 20 mg of iron in the diet in Western societies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homozygous HH is characterized by increased absorption of both heme and non-heme iron [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In contrast to normal subjects, the absorption of heme iron in HH is not regulated by iron stores. This leads to progressive iron accumulation because there is no normal mechanism for excretion of excess iron once it has been absorbed into the body.",
"   </p>",
"   <p>",
"    A few simple calculations explain why clinical manifestations of HH typically occur after age 40 in males and later in females. A male patient with homozygous HH absorbs 2 to 4 mg of iron per day, rather than the 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    needed to balance iron losses. Suppose that a patient absorbs 4",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The retention of 3 mg of iron more per day than is needed to maintain iron balance will lead to net iron accumulation of approximately 1 g per year. If there are no other major needs for iron following the adolescent growth spurt, it will not be until age 40 or 50 that total iron accumulation will reach more than 20 g of iron. Patients with this degree of iron overload are poised to develop the clinical features of HH described below. On the other hand, women become symptomatic later in life, because of the extra iron losses associated with menses, pregnancy, and lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HH and other iron overload states is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retained iron in HH is primarily deposited in parenchymal cells, with reticuloendothelial cell accumulation occurring very late in the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/16\">",
"     16",
"    </a>",
"    ]. This is in contrast to transfusional iron overload in which iron deposition occurs first in the reticuloendothelial cells and then in parenchymal cells.",
"   </p>",
"   <p>",
"    The clinical manifestations of iron accumulation include liver disease, skin pigmentation, diabetes mellitus, arthropathy, impotence in males, and cardiac enlargement with or without heart failure or conduction defects (",
"    <a class=\"graphic graphic_table graphicRef60117 \" href=\"UTD.htm?0/27/444\">",
"     table 2",
"    </a>",
"    ). One report, for example, evaluated 251 patients diagnosed with HH from 1959 to 1992. The following abnormalities were noted at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver function abnormalities &mdash; 75 percent",
"     </li>",
"     <li>",
"      Weakness and lethargy &mdash; 74 percent",
"     </li>",
"     <li>",
"      Skin hyperpigmentation &mdash; 70 percent",
"     </li>",
"     <li>",
"      Diabetes mellitus &mdash; 48 percent",
"     </li>",
"     <li>",
"      Arthralgia &mdash; 44 percent",
"     </li>",
"     <li>",
"      Impotence in males &mdash; 45 percent",
"     </li>",
"     <li>",
"      Electrocardiographic abnormalities &mdash; 31 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another report that involved 2851 respondents to a survey, symptoms had been present for an average of 10 years before diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/18\">",
"     18",
"    </a>",
"    ]. The most common symptoms were extreme fatigue (46 percent), arthralgia (44 percent), and loss of libido (26 percent).",
"   </p>",
"   <p>",
"    Skin hyperpigmentation reflects a combination of iron deposition and melanin. The classic triad of cirrhosis, diabetes mellitus, and skin pigmentation (\"bronze diabetes\") occurs late in the disease, at a time when the total body iron content has reached as much as 20 g (greater than five times normal).",
"   </p>",
"   <p>",
"    However, the presentation of HH has changed, since most patients are currently diagnosed when elevated serum iron levels are noted on a routine chemistry screening panel or screening is performed because of a relative diagnosed with HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. In two studies, approximately 75 percent of such patients were asymptomatic at presentation, with a low incidence (&lt;25 percent) of cirrhosis, diabetes, or skin hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As a result, correlations between the various HH genotypes on the one hand and clinical findings (eg, incidence of liver disease, nonalcoholic steatohepatitis, porphyria cutanea tarda, diabetes, arthritis) on the other, are of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third study evaluated 214 relatives with homozygous HH who were discovered during follow-up of 291 homozygous probands [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/22\">",
"     22",
"    </a>",
"    ]. The relatives were evaluated for the presence of iron overload and disease-related conditions (cirrhosis, hepatic fibrosis, elevated aminotransferase levels, and hemochromatotic arthropathy). Iron overload was present in 85 and 68 percent of the men and women, respectively, while the incidence of disease-related conditions was 38 and 10 percent, respectively. These observations highlight the importance of early diagnosis for the patient as well as for any undiagnosed affected relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive iron deposition is associated with hepatomegaly, elevated liver enzymes, and the eventual development of increasing fibrosis and cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Reversibility of these changes following therapeutic iron removal is more likely early in the course of the disease, but can occur even in patients with cirrhosis and varices [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/26\">",
"     26",
"    </a>",
"    ]. In one report of 120 patients with cirrhosis and HH and 120 patients with postnecrotic cirrhosis, 25 percent had varices [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/25\">",
"     25",
"    </a>",
"    ]. Therapeutic phlebotomy was associated with improvement or reversal of varices in 26 percent of patients with HH versus 5 percent in those with postnecrotic cirrhosis. Worsening portal hypertension in the patients with HH was associated with coexistent viral hepatic infection (eg, hepatitis B and C) in 16 of 22 cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron overload in HH also potentiates the development of alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This effect may be related to iron's ability to act as an electron donor, which accelerates the generation of unstable reactive oxygen intermediates, leading to enhanced membrane injury. Increased free radical formation may also hasten the generation of neutrophil chemoattractants, which further augment the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the number of patients studied to date is small, the presence of HH-induced iron overload may also have a potentiating effect on hepatic fibrosis in patients with hepatitis C virus (HCV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], similar to that seen in iron overloaded patients with thalassemia major and HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis of hepatic fibrosis\", section on 'Fibrogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link&amp;anchor=H11#H11\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\", section on 'Chronic hepatitis and liver fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with cirrhosis should undergo diagnostic endoscopy to document the presence of varices and to determine their risk for variceal hemorrhage. Patients at high risk for development of variceal hemorrhage should be considered for primary prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is one of the most serious complications of excess hepatic iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. Several studies have demonstrated an increased risk of HCC in patients with hereditary hemochromatosis, although estimates of the magnitude of risk have varied considerably ranging from a 20-fold to up to a 200-fold increase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/34,36-38\">",
"     34,36-38",
"    </a>",
"    ]. One of the largest population-based studies to address this issue estimated that the risk was increased approximately 20-fold compared with the general population (95% CI 16-22) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk was greatest in men and was not increased among first degree relatives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus (DM) is present in approximately 50 percent of patients with HH who present with symptoms. This complication is due to progressive iron accumulation in the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The defect appears to be relatively selective for the pancreatic beta cell; insulin and C-peptide secretion are reduced, but alpha cell function seems to be intact as evidenced by increased serum glucagon levels similar to those seen in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with HH and DM who require insulin may note a fall in insulin requirements following therapeutic iron removal.",
"   </p>",
"   <p>",
"    A separate issue is whether all patients with DM should be screened for hemochromatosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from Italy evaluated 894 diabetic patients (most with type 2 disease) for HH [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients underwent biochemical screening with transferrin saturation and serum ferritin and, after secondary causes of iron overload were excluded, liver biopsy to confirm the diagnosis. The prevalence of HH was 1.3 percent, six times that in the general population.",
"     </li>",
"     <li>",
"      In a study of 716 unselected Danish patients who developed type 1 diabetes after the age of 30, the prevalence of homozygosity for the C282Y mutation was 1.26 percent, almost five times that of a control population (odds ratio 4.6, 95 % CI: 2-10) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the latter two studies, an elevated transferrin saturation (&gt;50 or 55 percent) had a positive predictive value for HH of 26 to 39 percent after the first test and 80 percent after a second test, and a negative predictive value of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The positive predictive values were much lower for elevated serum ferritin levels, which, since ferritin is an acute phase reactant, can be the result of a variety of other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H7#H7\">",
"     \"Regulation of iron balance\", section on 'Ferritin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether all diabetic patients should be screened for HH is uncertain, since other studies have not confirmed the increased incidence of HH in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Most patients with diabetes secondary to hemochromatosis have other signs of HH such as liver disease or skin hyperpigmentation; thus, patients without these signs are less likely to have HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygotes for hemochromatosis are also at increased risk for developing DM. In a population-based study of 555 men from Finland, 6.9 percent were carriers of the gene for HH, with an associated increased risk of type 2 DM (odds ratio 3.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HH can be associated with an arthropathy that displays the full spectrum of calcium pyrophosphate crystal deposition disease (ie, pseudogout, chondrocalcinosis, and chronic arthropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The importance of iron accumulation in joint tissues in this setting is supported by reports of crystal deposition in patients with transfusion hemosiderosis as well as hemophilic arthritis. The arthropathy of iron overload is associated with characteristic radiologic findings: squared-off bone ends and hook-like osteophytes in the metacarpophalangeal (MCP) joints, particularly of the second and third MCP joints [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2265?source=see_link\">",
"     \"Rheumatic manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to many other manifestations of HH, symptoms of arthropathy do not generally respond to iron removal. In one series, for example, only 20 percent of 129 patients noted improvement in joint symptoms after phlebotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;HH can lead to a dilated cardiomyopathy characterized by the development of heart failure and conduction disturbances such as the sick sinus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/55-58\">",
"     55-58",
"    </a>",
"    ], due to excess deposition of iron within the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/59\">",
"     59",
"    </a>",
"    ]. In the past, cardiac disease was the presenting manifestation in up to 15 percent of patients with HH; thus, the absence of other characteristic findings of HH should not preclude the diagnosis.",
"   </p>",
"   <p>",
"    Cardiac involvement in hemochromatosis can often be diagnosed on the basis of history, clinical examination, laboratory testing and noninvasive imaging. Myocardial iron overload can be detected by cardiovascular magnetic resonance imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If other clinical evaluation is nondiagnostic, endomyocardial biopsy can be useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link&amp;anchor=H14#H14\">",
"     \"Endomyocardial biopsy\", section on 'Chronic DCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with phlebotomy or, in one report, chelation therapy has been associated with reversal of the left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. However, irreversible myocardial dysfunction can occur in subjects with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that iron overload might contribute to atherosclerosis. However, in atherosclerosis prone mice, dietary iron overload reduced the severity of atherosclerosis by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/60\">",
"     60",
"    </a>",
"    ]. Similar observations have been made in patients with HH; in an autopsy study, severe coronary artery disease occurred one-third as frequently in HH as in age- and sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/61\">",
"     61",
"    </a>",
"    ]. This subject remains controversial, with other studies showing an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/62-65\">",
"     62-65",
"    </a>",
"    ] or no relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/66-69\">",
"     66-69",
"    </a>",
"    ] between coronary artery disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemic cardiomyopathy on the one hand and either increased iron stores or heterozygosity for a HH mutation on the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemochromatosis is characterized by excess iron deposition in pituitary cells, leading to reduced serum levels of a number of trophic hormones. Iron accumulation is mostly in the anterior pituitary, while involvement of the posterior portion is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one study of 56 chronically transfused patients (52 with thalassemia major or intermedia), pituitary iron overload developed within the first decade of life, whereas significant pituitary volume loss was not observed until the second decade [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/72\">",
"     72",
"    </a>",
"    ]. Both pituitary iron overload and volume loss were independently predictive of hypogonadism, as defined by the timing of secondary sexual characteristics or the need for sex hormone replacement therapy. On magnetic resonance imaging, pituitary R2 correlated significantly with serum ferritin as well as with liver, pancreatic, and cardiac iron deposition by MRI.",
"   </p>",
"   <p>",
"    Secondary hypogonadism is the most common endocrine abnormality in HH, causing decreased libido and impotence in men. Other pituitary deficiencies may occur, but are much less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Hypogonadism may also contribute to the low bone mass commonly seen in patients with HH. In one series of 22 men with HH, 10 had osteoporosis; bone mass was lower in the five men who were hypogonadal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2265?source=see_link\">",
"     \"Rheumatic manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In three series of 89 men, 26 had low serum levels of testosterone, follicle stimulating hormone, and luteinizing hormone, indicating a pituitary origin for hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/73,74,76\">",
"     73,74,76",
"    </a>",
"    ]. Primary hypogonadism, presumably due to testicular iron deposition, also can occur, but is much less common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/73\">",
"     73",
"    </a>",
"    ]. Repeated phlebotomy to remove excess tissue iron deposits may reverse the hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/73,77,78\">",
"     73,77,78",
"    </a>",
"    ]. The age of the patient is important, since restoration of gonadal function primarily occurs in men under the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amenorrhea can occur in women but appears to be much less common than hypogonadism in men. One report of 23 women with homozygous HH found that none had loss of libido or natural menopause before age 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of 34 men with HH, three were hypothyroid with elevated levels of thyroid stimulating hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/79\">",
"     79",
"    </a>",
"    ]. These patients also had antithyroid antibodies, raising the possibility that iron deposition in the thyroid (documented in one case) caused tissue injury, leading to antigen exposure and the generation of antithyroid antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=see_link&amp;anchor=H30#H30\">",
"     \"Infiltrative thyroid disease\", section on 'Hereditary hemochromatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Extrahepatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated body iron stores have been associated with an increased risk of extrahepatic cancer in several reports, with a risk proportional to the degree of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/38,80-84\">",
"     38,80-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have found an increase in extrahepatic cancer risk among patients and families with iron overload. One of the largest population-based studies focused on 1847 patients with hereditary hemochromatosis and 5973 first-degree relatives. The risk of liver cancer in patients was increased approximately 20-fold compared with the general population. In contrast, the risk of all other cancers was not significantly increased in patients or their relatives.",
"   </p>",
"   <p>",
"    In contrast, in a 14 year follow-up study of large prospective cohort of 28,509 participants born in Australia, New Zealand, the United Kingdom, or Ireland, C282Y homozygotes, when compared with those with no C282Y variant, were found to have a significantly increased incidence of colorectal cancer (HR 2.28; 95% CI 1.22-4.25) and female breast cancer (HR 2.39; 95% CI 1.24-4.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/85\">",
"     85",
"    </a>",
"    ]. C282Y simple heterozygotes and",
"    <span class=\"nowrap\">",
"     C282Y/H63D",
"    </span>",
"    compound heterozygotes did not have an increased incidence of either of these two malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Susceptibility to specific infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemochromatosis with cirrhosis and transfusional iron overload in dialysis patients both appear to be risk factors for infection with Listeria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Iron overload of macrophages can diminish phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/86\">",
"     86",
"    </a>",
"    ], while high serum iron levels may increase bacterial virulence.",
"   </p>",
"   <p>",
"    Yersinia enterocolitica is another organism which may pose an increased risk of infection in iron overload states [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/88\">",
"     88",
"    </a>",
"    ]. This organism is siderophoric (iron-loving) and contains several pathways to facilitate iron uptake, which is essential for its growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=see_link\">",
"     \"Microbiology and pathogenesis of Yersinia infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Septicemia from Vibrio vulnificus, another iron-requiring bacterium, is more common in patients with HH who ingest uncooked seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. As a result, it has been recommended that patients with HH avoid consumption of uncooked seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link&amp;anchor=H6#H6\">",
"     \"Vibrio vulnificus infections\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Manifestations in heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of iron overload appear to be quite uncommon in patients who are heterozygous for HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/23,93\">",
"     23,93",
"    </a>",
"    ]. In a review of 1058 heterozygotes, approximately 10 percent had serum transferrin saturation values that were compatible with homozygous HH [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/93\">",
"     93",
"    </a>",
"    ]. Liver biopsy was performed in 39 patients. Six were abnormal but five had associated conditions (eg, hepatitis, alcohol). Thus, liver disease due to hemochromatosis alone is rare in heterozygotes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Iron status in HH heterozygotes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies of heterozygotes have suggested that these patients may be at increased risk for diabetes, colorectal cancer, and hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/82\">",
"     82",
"    </a>",
"    ]; these findings must be confirmed. As noted above, there are conflicting data as to whether the risk of cardiovascular disease is [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/64,65\">",
"     64,65",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/68\">",
"     68",
"    </a>",
"    ] modestly increased in HH heterozygotes. Of interest, the frequency of heterozygosity for the most common C282Y HH mutation was similar in 492 French centenarians (mean age 103 years, 8.9 percent) and 492 controls matched for sex and geographic origin (mean age 51, 8.5 percent), suggesting that heterozygosity for HH is not a risk factor for common life-threatening conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28617/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"       \"Patient information: Hemochromatosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12535812\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemochromatosis (HH) is an inherited disorder in which homozygosity or",
"    <span class=\"nowrap\">",
"     complex/double",
"    </span>",
"    heterozygosity for mutations in the HFE gene or other genes (",
"    <a class=\"graphic graphic_table graphicRef56329 \" href=\"UTD.htm?16/60/17356\">",
"     table 1",
"    </a>",
"    ) cause increased intestinal iron absorption, with resultant iron overload and tissue damage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major clinical manifestations of iron accumulation in advanced HH include liver disease, skin pigmentation, diabetes mellitus, arthropathy, impotence in males, and cardiac enlargement with or without heart failure or conduction defects (",
"      <a class=\"graphic graphic_table graphicRef60117 \" href=\"UTD.htm?0/27/444\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many subjects with HH are diagnosed when elevated serum iron or ferritin levels are noted on a routine chemistry screening panel or screening is performed because of a relative diagnosed with HH. The vast majority are asymptomatic, with a low incidence of cirrhosis, diabetes, or skin hyperpigmentation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Manifestations in heterozygotes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=see_link\">",
"       \"Screening for hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical manifestations of iron overload appear to be quite uncommon in patients who are heterozygous for HH. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Manifestations in heterozygotes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/1\">",
"      Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/2\">",
"      Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/3\">",
"      Pippard MJ. Detection of iron overload. Lancet 1997; 349:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/4\">",
"      Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/5\">",
"      Niederau C, Niederau CM, Lange S, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998; 128:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/6\">",
"      Camaschella C, Roetto A, Cicilano M, et al. Juvenile and adult hemochromatosis are distinct genetic disorders. Eur J Hum Genet 1997; 5:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/7\">",
"      Kelly AL, Rhodes DA, Roland JM, et al. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/8\">",
"      Camaschella C, Fargion S, Sampietro M, et al. Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 1999; 29:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/9\">",
"      De Gobbi M, Roetto A, Piperno A, et al. Natural history of juvenile haemochromatosis. Br J Haematol 2002; 117:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/10\">",
"      Vaiopoulos G, Papanikolaou G, Politou M, et al. Arthropathy in juvenile hemochromatosis. Arthritis Rheum 2003; 48:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/11\">",
"      Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/12\">",
"      Wurapa RK, Gordeuk VR, Brittenham GM, et al. Primary iron overload in African Americans. Am J Med 1996; 101:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/13\">",
"      Gordeuk VR, McLaren CE, Looker AC, et al. Distribution of transferrin saturations in the African-American population. Blood 1998; 91:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/14\">",
"      Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood 1989; 74:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/15\">",
"      Smith LH Jr. Pumping iron. West J Med 1995; 162:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/16\">",
"      Cairo G, Recalcati S, Montosi G, et al. Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. Blood 1997; 89:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/17\">",
"      Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol 1994; 356:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/18\">",
"      McDonnell SM, Preston BL, Jewell SA, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/19\">",
"      Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/20\">",
"      Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/21\">",
"      Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/22\">",
"      Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/23\">",
"      Powell LW, Jazwinska EC. Hemochromatosis in heterozygotes. N Engl J Med 1996; 335:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/24\">",
"      Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/25\">",
"      Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995; 22:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/26\">",
"      Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/27\">",
"      Irving MG, Halliday JW, Powell LW. Association between alcoholism and increased hepatic iron stores. Alcohol Clin Exp Res 1988; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/28\">",
"      St&aring;l P, Hultcrantz R. Iron increases ethanol toxicity in rat liver. J Hepatol 1993; 17:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/29\">",
"      Hultcrantz R, Bissell DM, Roll FJ. Iron mediates production of a neutrophil chemoattractant by rat hepatocytes metabolizing ethanol. J Clin Invest 1991; 87:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/30\">",
"      Diwakaran HH, Befeler AS, Britton RS, et al. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/31\">",
"      Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/32\">",
"      Fargion S, Fracanzani AL, Piperno A, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/33\">",
"      Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/34\">",
"      Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/35\">",
"      Niederau C, Fischer R, P&uuml;rschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/36\">",
"      Yang Q, McDonnell SM, Khoury MJ, et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/37\">",
"      Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985; 75:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/38\">",
"      Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995; 60:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/39\">",
"      Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/40\">",
"      Dymock IW, Cassar J, Pyke DA, et al. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972; 52:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/41\">",
"      Yaouanq JM. Diabetes and haemochromatosis: current concepts, management and prevention. Diabete Metab 1995; 21:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/42\">",
"      Nelson RL, Baldus WP, Rubenstein AH, et al. Pancreatic alpha-cell function in diabetic hemochromatotic subjects. J Clin Endocrinol Metab 1979; 49:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/43\">",
"      Conte D, Manachino D, Colli A, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998; 128:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/44\">",
"      Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/45\">",
"      Frayling T, Ellard S, Grove J, et al. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 1998; 351:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/46\">",
"      Sampson MJ, Williams T, Heyburn PJ, et al. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000; 135:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/47\">",
"      O'Brien T, Barrett B, Murray DM, et al. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care 1990; 13:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/48\">",
"      Salonen JT, Tuomainen TP, Kontula K. Role of C282Y mutation in haemochromatosis gene in development of type 2 diabetes in healthy men: prospective cohort study. BMJ 2000; 320:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/49\">",
"      Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/50\">",
"      Sinigaglia L, Fargion S, Fracanzani AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 1997; 24:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/51\">",
"      In&ecirc;s LS, da Silva JA, Malcata AB, Porto AL. Arthropathy of genetic hemochromatosis: a major and distinctive manifestation of the disease. Clin Exp Rheumatol 2001; 19:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/52\">",
"      Adamson, TC, Resnik, CS, Guerra, J Jr, et al. Hand and wrist arthropathies of hemochromatosis and calcium pyrophosphate deposition disease: Distinct radiographic features. Radiology 1983; 147:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/53\">",
"      Martel W, Champion CK, Thompson GR, Carter TL. A roentgenologically distinctive arthropathy in some patients with the pseudogout syndrome. Am J Roentgenol Radium Ther Nucl Med 1970; 109:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/54\">",
"      Smith LH Jr. Overview of hemochromatosis. West J Med 1990; 153:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/55\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med 1994; 331:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/56\">",
"      Rivers J, Garrahy P, Robinson W, Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 1987; 113:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/57\">",
"      Easley RM Jr, Schreiner BF Jr, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med 1972; 287:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/58\">",
"      Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986; 8:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/59\">",
"      Olson LJ, Edwards WD, McCall JT, et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987; 10:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/60\">",
"      Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001; 107:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/61\">",
"      Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994; 272:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/62\">",
"      Salonen JT, Nyyss&ouml;nen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/63\">",
"      Pereira AC, Cuoco MA, Mota GF, et al. Hemochromatosis gene variants in patients with cardiomyopathy. Am J Cardiol 2001; 88:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/64\">",
"      Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999; 100:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/65\">",
"      Tuomainen TP, Kontula K, Nyyss&ouml;nen K, et al. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland. Circulation 1999; 100:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/66\">",
"      M&auml;ntt&auml;ri M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994; 15:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/67\">",
"      Franco RF, Zago MA, Trip MD, et al. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol 1998; 102:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/68\">",
"      Waalen J, Felitti V, Gelbart T, et al. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med 2002; 113:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/69\">",
"      Ellervik C, Tybjaerg-Hansen A, Grande P, et al. Hereditary hemochromatosis and risk of ischemic heart disease: a prospective study and a case-control study. Circulation 2005; 112:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/70\">",
"      Fujisawa I, Morikawa M, Nakano Y, Konishi J. Hemochromatosis of the pituitary gland: MR imaging. Radiology 1988; 168:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/71\">",
"      Sondag MJ, Wattamwar AS, Aleppo G, Nemeth AJ. Case 179: Hereditary hemochromatosis. Radiology 2012; 262:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/72\">",
"      Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/73\">",
"      Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/74\">",
"      Walton C, Kelly WF, Laing I, Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. Q J Med 1983; 52:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/75\">",
"      Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/76\">",
"      Charbonnel B, Chupin M, Le Grand A, Guillon J. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 1981; 98:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/77\">",
"      Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion. J Clin Endocrinol Metab 1987; 65:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/78\">",
"      Cundy T, Butler J, Bomford A, Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 1993; 38:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/79\">",
"      Edwards CQ, Kelly TM, Ellwein G, Kushner JP. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 1983; 143:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/80\">",
"      Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/81\">",
"      Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/82\">",
"      Nelson RL, Davis FG, Persky V, Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer 1995; 76:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/83\">",
"      Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/84\">",
"      Gannon PO, Medelci S, Le Page C, et al. Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis. Int J Cancer 2011; 128:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/85\">",
"      Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010; 51:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/86\">",
"      van Asbeck BS, Verbrugh HA, van Oost BA, et al. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 1982; 284:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/87\">",
"      Mossey RT, Sondheimer J. Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 1985; 79:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/88\">",
"      Cherchi GB, Pacifico L, Cossellu S, et al. Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr Infect Dis J 1995; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/89\">",
"      Carniel E, Mazigh D, Mollaret HH. Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect Immun 1987; 55:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/90\">",
"      Gerhard GS, Levin KA, Price Goldstein J, et al. Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med 2001; 125:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/91\">",
"      Bullen JJ, Spalding PB, Ward CG, Gutteridge JM. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991; 151:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/92\">",
"      Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/93\">",
"      Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28617/abstract/94\">",
"      Coppin H, Bensaid M, Fruchon S, et al. Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene: case control study of 492 French centenarians. BMJ 2003; 327:132.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7167 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-01FC61200C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28617=[""].join("\n");
var outline_f27_60_28617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12535812\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gene defects other than HFE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Juvenile hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - African Americans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Extrahepatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Susceptibility to specific infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Manifestations in heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12535812\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7167\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7167|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17356\" title=\"table 1\">",
"      Variants hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/444\" title=\"table 2\">",
"      Evaluation of HH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=related_link\">",
"      Infiltrative thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=related_link\">",
"      Microbiology and pathogenesis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33258?source=related_link\">",
"      Pathogenesis of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=related_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2265?source=related_link\">",
"      Rheumatic manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_60_28618="Fluoroquinolones";
var content_f27_60_28618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fluoroquinolones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28618/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28618/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28618/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/60/28618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/60/28618/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/60/28618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluoroquinolones have become an increasingly popular class of antibiotics for use in a variety of infections. Newer drugs in this class have been developed with a broader spectrum of activity including better coverage of gram-positive organisms and, in one case, even anaerobes. However, toxicities have been associated with some of these newer agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grepafloxacin has been withdrawn from the market by the manufacturer because of adverse cardiac events.",
"     </li>",
"     <li>",
"      Sparfloxacin was withdrawn in February, 2001, primarily due to lack of sales [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trovafloxacin was withdrawn because of the risk of hepatic toxicity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"       Gatifloxacin",
"      </a>",
"      was withdrawn because of an increased frequency of hypoglycemia and hyperglycemia compared to other marketed fluoroquinolones. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Hypoglycemia and hyperglycemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       Gemifloxacin",
"      </a>",
"      has been approved for the treatment of mild to moderate community-acquired pneumonia and acute exacerbation of chronic bronchitis, but almost 14 percent of women under age 40 develop rash when taking the drug for longer than seven days. This adverse effect is largely avoided by use of a five day course of treatment. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Rash and other allergic manifestations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The spectrum of activity, mechanisms of action and resistance, pharmacokinetics, interactions with other drugs, and adverse effects of the fluoroquinolones will be reviewed here. The use of these drugs in a variety of specific infections is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones are the only class of antimicrobial agents in clinical use that are direct inhibitors of bacterial DNA synthesis. Fluoroquinolones inhibit two bacterial enzymes, DNA gyrase and topoisomerase IV, which have essential and distinct roles in DNA replication. The quinolones bind to the complex of each of these enzymes with DNA; the resulting complexes, including the drug, block progress of the DNA replication enzyme complex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/2\">",
"     2",
"    </a>",
"    ]. Ultimately, this action results in damage to bacterial DNA and bacterial cell death. Thus, fluoroquinolones are bactericidal agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to quinolones may occur via mutations in chromosomal genes or via mutations in plasmids; mutations in chromosomal genes occur in genes that [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encode the subunits of DNA gyrase and topoisomerase IV (altered target mechanism)",
"     </li>",
"     <li>",
"      Regulate the expression of cytoplasmic membrane efflux pumps or proteins that constitute outer membrane diffusion channels (altered permeation mechanism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of developing quinolone resistance is thought to be related to the intensity and duration of therapy. Support for the importance of duration comes from an in vitro model of Staphylococcus aureus infection, in which exposure to a quinolone for five days or more was associated with significant drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmid-mediated resistance to the fluoroquinolones has been reported in some clinical strains of Klebsiella pneumoniae, Escherichia coli, Enterobacter, and other enteric bacteria due to expression of one of several plasmid-encoded Qnr proteins, which appear to protect DNA gyrase from quinolone action [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Plasmids encoding Qnr proteins produce low-level quinolone resistance, but they also usually cause resistance to other classes of antibiotics and have been found in strains with additional chromosomal mutations, resulting in high-level quinolone resistance along with multidrug-resistance. Accumulation of mutations can result in highly resistant strains.",
"   </p>",
"   <p>",
"    In one study, 313 ceftazidime-resistant Enterobacteriaceae isolates collected in the United States between 1999 and 2004 were screened for the known qnr genes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/9\">",
"     9",
"    </a>",
"    ]. A qnr gene was present in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      20 percent of K. pneumoniae isolates",
"     </li>",
"     <li>",
"      31 percent of Enterobacter spp isolates",
"     </li>",
"     <li>",
"      4 percent of E. coli isolates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other plasmid-mediated resistance mechanisms have been more recently described and, like Qnr-mediated resistance, are linked to other antibiotic resistance genes on the same plasmid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one case, a fluoroquinolone-modifying enzyme evolved by mutation of a plasmid-encoded gene for an aminoglycoside acetyltransferase; this mediates low-level resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , as well as high-level resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/10\">",
"       10",
"      </a>",
"      ]. This enzyme variant has been present since at least 1999 and is now widely disseminated in enteric gram-negative bacteria such as E. coli, Klebsiella spp, and Enterobacter spp in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second case, a plasmid-encoded efflux pump, QepA, which pumps fluoroquinolones such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      out of the cell, confers low-level resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/12\">",
"       12",
"      </a>",
"      ]. Isolates encoding the QepA protein have been found in Europe, Japan, China, and North America, but usually only in low frequency. Another plasmid-encoded efflux pump, OqxAB, has been found in E. coli isolates from humans and swine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology of resistant strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, acquired fluoroquinolone resistance has been most frequent in methicillin-resistant strains of Staphylococcus aureus and in Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Fluoroquinolone use has also been identified as a risk factor for emergence of methicillin-resistant strains of S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of fluoroquinolone resistance in P. aeruginosa in hospitals is increasing and is related to increasing community and hospital use of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/15\">",
"     15",
"    </a>",
"    ]. Increases in quinolone resistance are also occurring in enteric bacteria in United States intensive care units often in association with resistance to other antimicrobials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outbreaks of resistant Neisseria gonorrhoeae are increasing in the United States and in other parts of the world. Based upon surveillance data demonstrating increasing rates of resistance, fluoroquinolones are no longer recommended for the treatment of gonorrhea in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistance in strains of Campylobacter jejuni has increased in patients with diarrhea due to this organism, with or without a history of foreign travel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the incidence of resistance is currently low in the United States, an increase in fluoroquinolone resistance among strains of Streptococcus pneumoniae has been reported in a number of countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquisition of resistance has frequently been associated with fluoroquinolone use in animals or humans. For Campylobacter infections, there was a temporal link between the use of quinolones in animal feed and the occurrence of resistant isolates in animals and humans. Nosocomial transmission and co-selection with the use of any antibiotic may also contribute to the high prevalence of resistance among methicillin-resistant, fluoroquinolone-resistant S. aureus. Resistant gonococci identified in outbreaks have been clonal, indicating person-to-person spread of these strains.",
"   </p>",
"   <p>",
"    A case-control study of nosocomial acquisition of fluoroquinolone-resistant strains of E. coli or K. pneumoniae also confirmed recent fluoroquinolone use as an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/23\">",
"     23",
"    </a>",
"    ]. Other independent risk factors in this study of 123 patients with fluoroquinolone-resistant organisms and 70 controls with fluoroquinolone-susceptible strains included: residence in a long-term care facility, recent aminoglycoside use, and older age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones, especially the newer agents, have a wide spectrum of activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Conventional bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest activity of the fluoroquinolones is against aerobic gram-negative bacilli, particularly Enterobacteriaceae, and against Haemophilus spp and gram-negative cocci such as Neisseria spp and Moraxella catarrhalis (",
"    <a class=\"graphic graphic_table graphicRef67649 graphicRef75299 \" href=\"UTD.htm?32/29/33246\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Relative to nalidixic acid, the fluoroquinolones have additional activity against non-enteric gram-negative bacilli such as Pseudomonas aeruginosa (",
"    <a class=\"graphic graphic_table graphicRef75299 \" href=\"UTD.htm?26/0/26637\">",
"     table 1B",
"    </a>",
"    ) and against staphylococci (",
"    <a class=\"graphic graphic_table graphicRef70191 \" href=\"UTD.htm?18/50/19245\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    remains the most potent marketed fluoroquinolone against gram-negative bacteria. For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , ciprofloxacin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , activity against streptococci and many anaerobes is limited (",
"    <a class=\"graphic graphic_table graphicRef70191 \" href=\"UTD.htm?18/50/19245\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81288 \" href=\"UTD.htm?4/3/4157\">",
"     table 3",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , however, have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluoroquinolone antibiotics are a promising new class of drugs for the treatment of tuberculosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    are active in vitro and in animal models of tuberculosis (",
"    <a class=\"graphic graphic_table graphicRef81288 \" href=\"UTD.htm?4/3/4157\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In patients with pulmonary tuberculosis, moxifloxacin has early bactericidal activity similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    but lower than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    and the long-acting rifamycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    , lower the plasma concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The clinical significance of this effect in patients with tuberculosis is unclear, since fluoroquinolone therapy is generally limited to isolates with resistance to multiple drugs, including the rifamycins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern has been raised that the widespread use of fluoroquinolones for the treatment of other bacterial infections may select for resistant strains of Mycobacterium tuberculosis. A study of two collections of M. tuberculosis isolates from the United States and Canada, one set containing multidrug-resistant strains, found that only 35 of 3225 strains tested (1 percent) were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    -resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/32\">",
"     32",
"    </a>",
"    ]. Studies are needed to evaluate the rates of resistance in other parts of the world.",
"   </p>",
"   <p>",
"    Another concern is that fluoroquinolone use could delay the diagnosis of tuberculosis because the culture might be converted to negative. A study of newly diagnosed tuberculosis cases found no association between prior fluoroquinolone exposure and culture-negative tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fluoroquinolones are also active against M. fortuitum, M. kansasii, and some strains of M. chelonae, but have only fair or poor activity against M. avium complex.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     Ofloxacin",
"    </a>",
"    has activity against M. leprae in animal models.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other bacteria are also inhibited by quinolones in vitro.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    have activity against the agents of atypical pneumonias, including Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila (formerly Chlamydia) pneumoniae, and against genital pathogens such as Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis (",
"    <a class=\"graphic graphic_table graphicRef67649 graphicRef75299 \" href=\"UTD.htm?32/29/33246\">",
"     table 1A-B",
"    </a>",
"    ). Treponema pallidum is resistant to ofloxacin in animal models, and no other quinolone has been shown to have activity against this spirochete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Newer quinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer fluoroquinolones have retained much of the activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    against enteric gram-negative bacteria. Ofloxacin is a racemic mixture of two stereoisomers, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    is composed solely of the active stereoisomer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, levofloxacin has the same spectrum of activity as ofloxacin but is generally twofold more potent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gram-negative organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    has a similar spectrum of activity as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    against gram-negative bacteria, but it is less active against Pseudomonas aeruginosa than ciprofloxacin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     Moxifloxacin",
"    </a>",
"    is less active than ciprofloxacin against P. aeruginosa, Providencia spp, Proteus spp, and Serratia marcescens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Respiratory pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the newer quinolones, as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , are highly active against H. influenzae and M. catarrhalis. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    exhibit increased potency relative to ciprofloxacin and ofloxacin against Streptococcus pneumoniae (MIC90 values of 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for levofloxacin and 0.12 to 0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for moxifloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     Gemifloxacin",
"    </a>",
"    is distinctive for its unusually high potency against pneumococci (MIC90 value of 0.03",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/38\">",
"     38",
"    </a>",
"    ]. Other respiratory pathogens, such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae, are also highly susceptible to the newer quinolones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gram-positive organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the newer quinolones all have increased potency relative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    against other gram-positive cocci in addition to S. pneumoniae, they have a more limited role in the treatment of staphylococcal and enterococcal infections because of marginal intrinsic potency or acquired resistance. Among staphylococci, most methicillin-susceptible strains of Staphylococcus aureus are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (MIC90 of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/39\">",
"     39",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (MIC90 of 0.12",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/37\">",
"     37",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    (MIC90 of 0.03",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, many methicillin-resistant strains of S. aureus have acquired high-level resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    that causes substantial cross-resistance to all of the newer agents. These same patterns of differing quinolone susceptibility have been seen with methicillin-susceptible and -resistant strains of coagulase-negative staphylococci. Activity against enterococci is marginal, with MIC90 values of 3.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and 0.5 to 8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/37,41\">",
"     37,41",
"    </a>",
"    ]. Vancomycin-resistant enterococci (which in the United States are often Enterococcus faecium) often have MIC values at the high end of these ranges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the available quinolones, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    has sufficient activity against anaerobic bacteria for potential clinical applicability (",
"    <a class=\"graphic graphic_table graphicRef81288 \" href=\"UTD.htm?4/3/4157\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/42\">",
"     42",
"    </a>",
"    ]. In a double-blind, randomized trial of patients with complicated intraabdominal infections, moxifloxacin was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/43\">",
"     43",
"    </a>",
"    ]. The clinical outcomes were comparable in both arms with higher eradication rates for Bacteroides spp in the moxifloxacin arm.",
"   </p>",
"   <p>",
"    Bacteroides fragilis and other Bacteroides species may be susceptible, but some studies have already noted resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    in 25 to 30 percent of strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaerobic bacterial infections\", section on 'Antibiotic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quinolones are well absorbed from the upper gastrointestinal tract, with bioavailability exceeding 50 percent for all compounds and approaching 100 percent for several (",
"    <a class=\"graphic graphic_table graphicRef72974 \" href=\"UTD.htm?40/3/41020\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    all have oral and intravenous formulations that allow direct estimates of oral bioavailability, with values of 70 percent for ciprofloxacin, &gt;95 percent for ofloxacin and levofloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/49\">",
"     49",
"    </a>",
"    ], and 86 percent for moxifloxacin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     Gemifloxacin",
"    </a>",
"    is only available as an oral formulation.",
"   </p>",
"   <p>",
"    Peak concentrations in serum are usually attained within one to three hours of administering an oral dose. Food does not substantially reduce quinolone absorption but may delay the time to reach peak drug concentrations in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Absorption is good when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is given by nasogastric or jejunostomy tube but may be decreased by concurrent enteral feedings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drug concentrations in serum and other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak fluoroquinolone concentrations in serum after usual doses in the range of 200 to 500 mg are highest for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (5.7 to 6.4",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    and lowest for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    (both about 1.5",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/40,53-55\">",
"     40,53-55",
"    </a>",
"    ]. The volumes of distribution of quinolones are high and in most cases exceed the volume of total body water, indicating accumulation in some tissues. Concentrations in prostate tissue, stool, bile, lung, and neutrophils as well as macrophages usually exceed serum concentrations. Concentrations in urine and kidney tissue are high for the quinolones with a major renal route of elimination (all except",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ). Concentrations of quinolones in saliva, prostatic fluid, bone, and cerebrospinal fluid are usually lower than drug concentrations in serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Half-lives of the drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminal half-lives of elimination from serum range from three hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    to six to eight hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    , allowing twice- or once-daily dosing. Although levofloxacin has only a slightly longer half-life than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , it is given at a somewhat higher dose (with a twofold greater potency) once rather than twice a day, based upon pharmacodynamic modeling of quinolones that indicates concentration-dependent bacterial killing and post-antibiotic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/56\">",
"     56",
"    </a>",
"    ], similar to what is seen with the aminoglycosides. The half-lives of moxifloxacin and gemifloxacin support once daily dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Routes of elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal routes of elimination differ among quinolones.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     Ofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    are eliminated predominantly by the kidneys, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    is eliminated predominantly by nonrenal pathways. Most other quinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) have mixed excretion by both renal and nonrenal routes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Renal clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    exceeds glomerular filtration rates (GFR), indicating net tubular secretion. In support of tubular secretion, renal clearances of norfloxacin and ciprofloxacin are reduced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hepatic and biliary excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic conversion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    to less active metabolites accounts for 10 to 20 percent of elimination. There is minimal hepatic biotransformation (&lt;10 percent) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    . Hepatic metabolism and biliary excretion are the principal routes of elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (intact parent compound in feces 25 percent, sulfated metabolite 38 percent; glucuronide 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition to glucuronide conjugates and desmethyl piperazinyl derivatives, other metabolites of quinolones that have been identified have predominantly had alterations of the piperazine ring, including N-oxide, N-sulfo, N-formyl, and desethylene derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/46,58,59\">",
"     46,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dose adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose adjustments in renal failure and hepatic failure differ. The following adjustments refer to patients with impaired renal function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No dose adjustment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      is necessary in the presence of renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/36,60\">",
"       36,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      should be reduced in patients with creatinine clearances below 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/34,61\">",
"       34,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      should be reduced in those with creatinine clearances below 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Clearance by hemodialysis is low (approximately 14 percent of plasma clearance) for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      . No dose adjustment is needed for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Continuous venovenous hemofiltration results in some elimination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      , but doses of 400 mg ciprofloxacin daily and 250 mg levofloxacin daily are sufficient to maintain therapeutic levels [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/62\">",
"       62",
"      </a>",
"      ]. Dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      should be the same as in patients with normal renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peritoneal dialysis contributes little to the clearance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with hepatic failure (without renal dysfunction), no adjustment in dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    is generally necessary and increases in half-lives have not been seen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    in patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/65\">",
"     65",
"    </a>",
"    ]. For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , no adjustment is necessary for patients with Childs-Pugh class A cirrhosis; no data are available on classes B and C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety in pregnancy has not been established for any of the quinolones, but studies of babies born to women exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    during the first trimester have not identified any increased teratogenic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In one prospective cohort study comparing 200 women exposed to fluoroquinolones and 200 women exposed to known non-embryotoxic antibiotics, there were no differences in birth defects, spontaneous abortions, prematurity, or fetal distress, but a higher rate of therapeutic abortions, suggesting that concerns about teratogenic risks may exceed the actual risks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/67\">",
"     67",
"    </a>",
"    ]. Because quinolones are excreted in breast milk, they should be avoided for nursing mothers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones are not recommended for routine use in children &lt;18 years of age because studies in immature animals have demonstrated the development of arthropathy with erosions of the cartilage in weight-bearing joints.",
"   </p>",
"   <p>",
"    There is an evolving view, based upon the absence of arthropathy in humans seen over the past decades of fluoroquinolone use, that in some children, particularly those with cystic fibrosis, the benefit of quinolones outweighs what appears to be a small short-term risk of joint toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Expanded use of quinolones in pediatrics is under consideration and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    has been approved for use in children with complicated urinary tract infections and pyelonephritis (See appropriate pediatric drug information topic reviews by searching on the drug name).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tolerability of the fluoroquinolones is best assessed in double-blind randomized trials in which the effects of patient populations, methods of ascertainment, and possible bias can be controlled. The side-effect profiles have been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In some cases, uncommon side effects were only recognized with more extensive clinical use after regulatory approval. Common adverse effects associated with fluoroquinolones include gastrointestinal and central nervous system toxicities. Other adverse effects include rashes and other allergic reactions, tendinitis and tendon rupture, QT prolongation, hypoglycemia and hyperglycemia, and hematologic toxicity.",
"   </p>",
"   <p>",
"    While the fluoroquinolone drugs are generally well-tolerated, grepafloxacin was removed from the market worldwide by the manufacturer due to seven fatal cardiovascular events in patients on the drug and three cases of torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/72\">",
"     72",
"    </a>",
"    ]. Trovafloxacin was removed from the market by the manufacturer due to reports of liver failure. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'QT interval prolongation and arrhythmia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31\">",
"     'Transaminitis and liver failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent category of adverse effect involves the gastrointestinal tract, occurring in 3 to 17 percent of patients reported in clinical trials. In most patients, anorexia, nausea, vomiting, and abdominal discomfort are mild when they occur. Diarrhea is less frequent.",
"   </p>",
"   <p>",
"    In institutional settings with outbreaks of the epidemic fluoroquinolone-resistant strain of Clostridium difficile, use of fluoroquinolones has been a risk factor for development of C. difficile-associated diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next most frequent category of adverse effects after gastrointestinal toxicity involves the central nervous system, occurring in 0.9 to 11 percent of patients. Symptoms of mild headache and dizziness have predominated, followed by insomnia and alterations in mood. Dizziness has been reported in up to 11 percent of patients receiving trovafloxacin at 200 mg PO once daily. Hallucinations, delirium, and seizures are rare. Seizures may have resulted in some, but not all cases, from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    accumulation or from the ability of theophylline and NSAIDs to augment fluoroquinolone-mediated displacement of GABA from its receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in individuals with myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/75\">",
"     75",
"    </a>",
"    ]. Postmarketing reports have included death and respiratory failure requiring mechanical ventilation in patients with myasthenia gravis receiving fluoroquinolones. Thus, fluoroquinolones should be avoided in individuals with myasthenia gravis.",
"    <br/>",
"    <br/>",
"    Sensory or sensorimotor axonal polyneuropathy affecting small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported rarely in patients receiving fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/76\">",
"     76",
"    </a>",
"    ]. Fluoroquinolones should be discontinued in patients who experience symptoms of neuropathy in order to prevent the development of an irreversible condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Rash and other allergic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic and skin reactions have occurred in 0.4 to 2.2 percent of patients taking fluoroquinolones. Unspecified rashes have been most frequent. The newest fluoroquinolone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    , has been studied prospectively and found to cause a mild rash in 2.8 percent of patients overall, but an unexpectedly high rate (14 percent) in women under 40 years of age who received the drug for seven or more days. If the duration of therapy is limited to five days, rash occurs in 1.2 to 2.1 percent of patients. A second course of gemifloxacin should not be given to patients who developed a rash during an initial course. It is unclear if such patients are at increased risk for rash if other fluoroquinolones are given subsequently.",
"   </p>",
"   <p>",
"    Phototoxicity reactions also occur in some patients after exposure to UVA (320 to 400 nm) light and appear to be more frequent with lomefloxacin and sparfloxacin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. Both of these agents have a halide substituent at the 8 position, which is known to increase phototoxicity, but neither is available for clinical use any longer. The methoxy group found at the 8 position in moxifloxacin and gatifloxacin reduces phototoxic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Light in the UVA range is not blocked by many sunscreens, which often contain only UVB blockers. Products containing UVA blockers such as octocrylene or Parsol 1789 may afford some protection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/70\">",
"     70",
"    </a>",
"    ], although the value of these agents in protecting against fluoroquinolone phototoxicity has not been systematically evaluated.",
"   </p>",
"   <p>",
"    Drug fever, urticaria, angioedema, vasculitis, serum sickness-like syndromes, and anaphylactoid or anaphylactic reactions have been uncommon; occasional fatal hypersensitivity reactions have been reported with fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. Acute interstitial nephritis also occurs infrequently and has been associated with eosinophiluria, but generally not crystalluria. Infiltrates of lymphocytes and eosinophils has been found in the renal interstitium on renal biopsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthropathy with cartilage erosions and noninflammatory effusions occurs in the weight-bearing joints of juvenile animals given quinolones. Experience with use of quinolones in children has increased, particularly in children with cystic fibrosis given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    . These children and others receiving nalidixic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    have only uncommonly had joint symptoms, which have been reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/68,87\">",
"     68,87",
"    </a>",
"    ]. Studies to identify subclinical cartilage damage by magnetic resonance imaging of joints of treated children have also been negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Use in children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Tendinopathy and tendon rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendinopathy and tendon rupture have been reported uncommonly in adults given fluoroquinolones but have been reported with most fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/89-95\">",
"     89-95",
"    </a>",
"    ]. Although these adverse effects have involved the Achilles tendon in the majority of cases, they have also been reported to occur in the rotator cuff (shoulder), hand, biceps, thumb, and other tendon sites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) requires drug manufacturers to include a boxed warning regarding the increased risk of tendinopathy and tendon rupture associated with fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/94\">",
"     94",
"    </a>",
"    ]. The FDA recommends that at the first sign of tendon pain, swelling, or inflammation, patients should stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician for tendon evaluation and transition to a non-fluoroquinolone antibiotic.",
"   </p>",
"   <p>",
"    In a database study of 6.4 million patients, 28,907 cases of Achilles tendinopathy and 7685 cases of tendon rupture were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/95\">",
"     95",
"    </a>",
"    ]. Use of a fluoroquinolone was strongly associated with Achilles tendinopathy (odds ratio [OR] 4.3, 95% CI 3.2-5.7) and tendon rupture (OR 2.0, 95% CI 1.2-3.3). The association with Achilles tendinopathy was stronger among individuals who were &gt;60 years old (OR 8.3 vs 1.6), nonobese (OR 7.7 versus 2.4), and those using oral glucocorticoids (OR 9.1 versus 3.2). Female sex was significantly associated with tendon rupture (OR 4.0 versus 1.1).",
"   </p>",
"   <p>",
"    Kidney, heart, and lung transplantation have been identified as additional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/94\">",
"     94",
"    </a>",
"    ]. The median duration of fluoroquinolone use before the onset of tendon injury is eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/93\">",
"     93",
"    </a>",
"    ]. The risk of tendinopathy may be exposure-related; dosages should be adjusted based on renal function to avoid possible drug accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Achilles tendinopathy and tendon rupture is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=see_link\">",
"     \"Achilles tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     QT interval prolongation and arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;QT interval prolongation due to inhibition of potassium channels encoded by the HERG gene has been described with a variety of fluoroquinolones and other drugs (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/97\">",
"     97",
"    </a>",
"    ]. QT prolongation is associated with an increased risk of a characteristic life-threatening cardiac arrhythmia, known as torsades de pointes (TdP) (",
"    <a class=\"graphic graphic_waveform graphicRef77018 graphicRef53891 \" href=\"UTD.htm?1/40/1672\">",
"     waveform 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree to which fluoroquinolones block cardiac potassium channels and thereby cause QT prolongation varies by agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Sparfloxacin has the most potent inhibitory effect followed by grepafloxacin, both of which have been removed from the market [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/100\">",
"     100",
"    </a>",
"    ]. Gatifloxacin and moxifloxacin have a moderate inhibiting effect on potassium channels, whereas levofloxacin, ciprofloxacin, and ofloxacin have relatively minor effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/96,97,99\">",
"     96,97,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a nested case-control analysis that included 605,127 patients receiving treatment for respiratory conditions, 1838 cases of serious arrhythmia were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/101\">",
"     101",
"    </a>",
"    ]. The rate of serious arrhythmia was elevated with current fluoroquinolone use (relative risk [RR] 1.76, 95% CI 1.19-2.59), particularly with new current use (RR 2.23, 95% CI 1.31-3.80).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     Gatifloxacin",
"    </a>",
"    was associated with the highest rate of serious arrhythmia (RR 7.38, 95% CI 2.30-23.70), but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (RR 3.30, 95% CI 1.47-7.37) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (RR 2.15, 95% CI 1.34-3.46) were also associated with elevated rates.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     Levofloxacin",
"    </a>",
"    did not appear to increase the rate of serious arrhythmia. Despite the elevated rate of serious arrhythmia observed with ciprofloxacin in this study, in a large database analysis, ciprofloxacin was not associated with an increased risk of cardiovascular mortality; it was unclear whether or not levofloxacin was associated with an increased risk of cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/102\">",
"     102",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA)-approved product information for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    each state that QT prolongation has been observed in some patients receiving these drugs, and post-marketing events include rare reports of ventricular tachyarrhythmias including torsades de pointes and cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/83,84,86,103\">",
"     83,84,86,103",
"    </a>",
"    ]. The risk of QT prolongation appears to be increased in elderly and female patients and those with existing QT prolongation or known risk factors. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Drug interactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With any of the fluoroquinolones, caution is warranted when administered to patients who are also being treated with other drugs that prolong the QT interval (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ). An alternative regimen may be warranted.",
"   </p>",
"   <p>",
"    Recommendations in the US FDA-approved product information vary with the specific fluoroquinolone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States product information for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"       gemifloxacin",
"      </a>",
"      recommend that these agents be avoided in patients with known QT interval prolongation or other risk factors for torsade de pointes, such as hypokalemia, hypomagnesemia, or the use of class IA (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ) or class III (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ) antiarrhythmic drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/83,84,103\">",
"       83,84,103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      should be used with caution in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United States product information for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      further suggests caution in use by patients with hepatic insufficiency-associated metabolic disturbances, which may lead to QT prolongation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Transaminitis and liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trovafloxacin is a fluoroquinolone that was associated with fatal liver failure in post-marketing reports, and as a result was removed from clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/82\">",
"     82",
"    </a>",
"    ]. Hepatotoxicity can also occur with other fluoroquinolones, but the frequency appears to vary with different fluoroquinolones as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based nested case-control study using data from more than 1.5 million outpatients over the age of 65 with no prior history of liver disease, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      (adjusted odds ratio [aOR] 2.20, 95% CI 1.21-3.98) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (aOR 1.85, 95% CI 1.01-3.39) were associated with an increased risk of hospital admission for acute liver injury within 30 days of receiving a prescription compared with use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (an antibiotic that is rarely associated with liver injury) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/104\">",
"       104",
"      </a>",
"      ]. No increased risk was observed for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      compared with clarithromycin.",
"     </li>",
"     <li>",
"      The United States Food and Drug Administration has reported acute liver failure in 58 cases per 10 million prescriptions of trovafloxacin, 6.6 cases per 10 million prescriptions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , 6.0 cases per 10 million prescriptions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"       gatifloxacin",
"      </a>",
"      , and 2.1 cases per 10 million prescriptions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective study conducted by the Drug-induced Liver Injury Network, 12 of 679 patients who had received a fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    ) had hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/106\">",
"     106",
"    </a>",
"    ]. The median time between initiating the fluoroquinolone and the development of symptoms was four days (range 1 to 39 days). Nine patients developed symptoms while taking the fluoroquinolone, whereas three developed symptoms 2 to 32 days after stopping it. One third of patients had hepatocellular injury, one third had cholestatic injury, and one third had both. Most patients had mild disease, but two patients with hepatocellular injury and jaundice died, one of acute liver failure. One patient with cholestatic injury developed vanishing bile duct syndrome and required liver transplantation. Another patient with cholestatic injury had a persistently elevated serum alkaline phosphatase concentration. Seven patients had rash, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilia, suggesting an immunoallergic reaction; this type of reaction was also seen with trovafloxacin-associated hepatotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hypoglycemia and hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic hypoglycemia and hyperglycemia have been reported in the postmarketing period for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The frequency of glucose homeostasis abnormalities reported to the FDA associated with gatifloxacin was significantly higher than those events reported with other fluoroquinolones (477 versus 4, 11, and 39 per 10",
"    <sup>",
"     7",
"    </sup>",
"    retail prescriptions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , respectively); 25 cases were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/109\">",
"     109",
"    </a>",
"    ]. As a result, gatifloxacin was withdrawn from the market in the United States and Canada in June 2006.",
"   </p>",
"   <p>",
"    Population-based, nested case-control studies identified adults &ge;66 years of age who were treated in the hospital for hypoglycemia (788 patients) or hyperglycemia (470 patients) after outpatient treatment with a macrolide, second-generation cephalosporin, or respiratory fluoroquinolone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/110\">",
"     110",
"    </a>",
"    ]. As compared with macrolide treatment,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    were associated with an increased risk of hypoglycemia (adjusted odds ratio 4.3, 95% CI 2.9-6.3; and 1.5, 95% CI 1.2-2.0; respectively). No increased risk was seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or cephalosporins. Gatifloxacin as compared with macrolides was also significantly associated with hyperglycemia (adjusted odds ratio, 16.7, 95% CI 10.4-26.8). No increased risk for hyperglycemia was seen with the other antibiotics. Risks were similar regardless of the presence or absence of diabetes. These effects have been associated with drug-induced changes in insulin secretion.",
"   </p>",
"   <p>",
"    Another retrospective cohort study showed an elevated risk of both severe hypoglycemia and hyperglycemia associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    use among diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/111\">",
"     111",
"    </a>",
"    ]. In patients with diabetes, the odds ratio for hypoglycemia compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    was 4.3 (95% CI 2.7-6.6) for gatifloxacin, 2.1 (95% CI 1.4-3.3) for levofloxacin, and 1.1 (95% CI 0.6-2.0) for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    . The odds ratio for hyperglycemia compared with azithromycin among diabetics was 4.5 (95% CI 3.0-6.9) for gatifloxacin, 1.8 (95% CI 1.2-2.7) for levofloxacin, and 1.0 (95% CI 0.6-1.8) for ciprofloxacin. Thus, the risk of both hypoglycemia and hyperglycemia are significantly elevated in diabetic patients taking gatifloxacin or levofloxacin, but not ciprofloxacin. There was an insufficient number of hypoglycemic or hyperglycemic events among non-diabetics to assess a possible association between fluoroquinolone use and dysglycemia in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia and eosinophilia generally occur in less than 1 percent of patients; these abnormalities are rarely of sufficient severity to require cessation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H142842158\">",
"    <span class=\"h2\">",
"     Retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nested case-control study of patients who had visited an ophthalmologist found an increased rate of retinal detachment in patients who were currently receiving an oral fluoroquinolone (3.3 percent of cases versus 0.6 percent of controls, adjusted odds ratio 4.5, 95% CI 3.6-5.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/112\">",
"     112",
"    </a>",
"    ]. Neither recent use nor past use of a fluoroquinolone was associated with retinal detachment, suggesting that retinal detachment may be an acute adverse effect. The absolute increase in the risk of retinal detachment in patients receiving a fluoroquinolone was 4 per 10,000 person-years; the number needed to harm was 2500 for any use of fluoroquinolones. No such effect was found with beta-lactam antibiotics. A possible reason for the increased risk of retinal detachment in patients taking a fluoroquinolone could be the effect of this class of agents on collagen and connective tissue. This adverse effect requires confirmation in an additional study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones can interact with a variety of other drugs. This section will review the most important or frequent interactions; a complete listing is provided separately for each fluoroquinolone (see appropriate drug information topic reviews by searching on the drug name). In addition, specific interactions of fluoroquinolones with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.",
"   </p>",
"   <p>",
"    When coadministered by mouth with aluminum-, magnesium-, or, to a lesser extent, calcium-containing antacids, quinolones have markedly reduced oral bioavailability, presumably because of the formation of cation&ndash;quinolone complexes, which are poorly absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/113\">",
"     113",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     Sucralfate",
"    </a>",
"    , which contains large amounts of aluminum ions, also reduces absorption of quinolones. Although staggering of doses of antacids and quinolones may reduce this interaction, there is sufficient variability to suggest that this maneuver may not be fully reliable in an individual patient. Generally, H2-receptor antagonists and proton pump inhibitors do not have important effects on absorption of quinolones.",
"   </p>",
"   <p>",
"    Concurrent administration of quinolones with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    , multivitamin-mineral regimens containing zinc, and the buffered formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have also been reported to reduce quinolone absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/114\">",
"     114",
"    </a>",
"    ]. Nutritional supplements given by nasogastric tube may reduce the absorption of quinolones given concurrently by the same route, likely because these supplements also contain multivalent cations such as iron and zinc.",
"   </p>",
"   <p>",
"    For the intravenous formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , precipitates have been reported when this preparation was infused through the same intravenous tubing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    with and without clavulanate, or flucloxacillin. Thus, separate infusions are indicated.",
"   </p>",
"   <p>",
"    Quinolones vary in the extent to which they impair the elimination of the methylxanthines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and caffeine. The effects appear to result from inhibition by some quinolones of hepatic cytochrome P450 isozyme 1A2, which is involved in theophylline and caffeine metabolism. Some effects are seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (20 to 90 percent increase), but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/60/12231?source=see_link\">",
"     gemifloxacin",
"    </a>",
"    have little or no effect (2 to 11 percent increases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. In patients receiving ciprofloxacin in combination with theophylline, serum levels of theophylline should be monitored and reductions in the dose of theophylline considered.",
"   </p>",
"   <p>",
"    Nonsteroidal anti-inflammatory drugs (NSAIDs) may affect the central nervous system stimulant effects of quinolones. Seizures were reported in a group of Japanese patients receiving enoxacin and the NSAID fenbufen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/117\">",
"     117",
"    </a>",
"    ]. Potentiation of seizures by combinations of quinolones and NSAIDs has also been reported in animals. Quinolones displace the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) from its receptors in rat brain tissue, and this displacement is enhanced by fenbufen and theophylline. The extent to which concurrent use of quinolones with other NSAIDs results in central nervous system toxicities is unclear, but patients receiving both classes of drugs should be cautioned about and monitored for these adverse effects.",
"   </p>",
"   <p>",
"    As noted above, fluoroquinolones can prolong QT interval by inhibiting potassium channels involved in cardiac repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/98\">",
"     98",
"    </a>",
"    ]. This effect may be augmented if fluoroquinolones are given together with any of the multiple other drugs that cause QT prolongation, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H30\">",
"     'QT interval prolongation and arrhythmia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such interactions may increase the risk of torsades de pointes and sudden death. Thus, fluoroquinolones should usually",
"    <strong>",
"     not",
"    </strong>",
"    be given together with other drugs known to prolong the QT interval. Specific drug combinations that should be avoided are discussed above. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'QT interval prolongation and arrhythmia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other types of drug interactions have been studied less extensively.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    appears not to affect the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    . Ciprofloxacin has had effects on the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Enoxacin and ciprofloxacin have been shown to reduce the clearance of the less active R-enantiomer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , but have no clinically important effect on the more active S-enantiomer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/60/28618/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527964309\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluoroquinolones are the only class of antimicrobial agents in clinical use that are direct inhibitors of bacterial DNA synthesis. They inhibit two bacterial enzymes, DNA gyrase and topoisomerase IV, which have essential and distinct roles in DNA replication. The fluoroquinolones are bactericidal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several mechanisms of resistance to fluoroquinolones have been described, including both chromosomal and plasmid-mediated mechanisms. Plasmid-mediated mechanisms are almost always associated with resistance to other antibiotics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluoroquinolones, especially the newer agents, have a wide spectrum of activity that includes gram-negative bacilli, Streptococcus pneumoniae and other respiratory pathogens, other gram-positive cocci, and mycobacterial species. The specific antimicrobial spectrum varies with the different fluoroquinolones (",
"      <a class=\"graphic graphic_table graphicRef67649 \" href=\"UTD.htm?20/1/20509\">",
"       table 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75299 \" href=\"UTD.htm?26/0/26637\">",
"       table 1B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70191 \" href=\"UTD.htm?18/50/19245\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81288 \" href=\"UTD.htm?4/3/4157\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fluoroquinolones are well absorbed from the upper gastrointestinal tract, with bioavailability exceeding 50 percent for all compounds and approaching 100 percent for several (",
"      <a class=\"graphic graphic_table graphicRef72974 \" href=\"UTD.htm?40/3/41020\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal routes of elimination differ among fluoroquinolones.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       Ofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      are eliminated predominantly by the kidneys, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      is eliminated predominantly by nonrenal pathways. Most other fluoroquinolones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ) have mixed excretion by both renal and nonrenal routes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Routes of elimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects most commonly associated with fluoroquinolones include gastrointestinal and central nervous system toxicities. Other adverse effects include rashes and other allergic reactions, tendinitis and tendon rupture, QT prolongation, hepatotoxicity, hypoglycemia and hyperglycemia, hematologic toxicity, and retinal detachment. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluoroquinolones can interact with a variety of other drugs. A common problem is that coadministration of fluoroquinolones with aluminum-, magnesium-, or, to a lesser extent, calcium-containing antacids, leads to markedly reduced oral bioavailability of the quinolone, presumably because of the formation of cation&ndash;quinolone complexes, which are poorly absorbed. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The QT prolonging effects of fluoroquinolones may be augmented if fluoroquinolones are given together with any of the multiple other drugs that cause QT prolongation, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"       table 5",
"      </a>",
"      ). These interactions may increase the risk of torsades de pointes and sudden death. Thus, fluoroquinolones should",
"      <strong>",
"       not",
"      </strong>",
"      be given together with other drugs known to prolong the QT interval. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific interactions of fluoroquinolones with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mylan Zagam discontinued: Charges total $4.7 mil in fiscal third quarter. In: \"The Pink Sheet\" vol. 63 no. 6. F-D-C Reports, Inc. Chevy Chase, Maryland 2001. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/2\">",
"      Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/3\">",
"      Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/4\">",
"      Tam VH, Louie A, Fritsche TR, et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007; 195:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/5\">",
"      Mart&iacute;nez-Mart&iacute;nez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/6\">",
"      Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci U S A 2002; 99:5638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/7\">",
"      Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/8\">",
"      Pitout JD, Wei Y, Church DL, Gregson DB. Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6')-Ib-cr. J Antimicrob Chemother 2008; 61:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/9\">",
"      Robicsek A, Strahilevitz J, Sahm DF, et al. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006; 50:2872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/10\">",
"      Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/11\">",
"      Park CH, Robicsek A, Jacoby GA, et al. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006; 50:3953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/12\">",
"      P&eacute;richon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 2007; 51:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/13\">",
"      Zhao J, Chen Z, Chen S, et al. Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. Antimicrob Agents Chemother 2010; 54:4219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/14\">",
"      Coronado VG, Edwards JR, Culver DH, et al. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/15\">",
"      Polk RE, Johnson CK, McClish D, et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/16\">",
"      Weber SG, Gold HS, Hooper DC, et al. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/17\">",
"      Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/18\">",
"      Fox KK, Knapp JS, Holmes KK, et al. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones. J Infect Dis 1997; 175:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/20\">",
"      Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999; 340:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/21\">",
"      Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/22\">",
"      Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/23\">",
"      Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162:2469.",
"     </a>",
"    </li>",
"    <li>",
"     Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Quinolone antimicrobial agents, 2nd ed, Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC 1993. p.161.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/25\">",
"      Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/26\">",
"      Ji B, Lounis N, Maslo C, et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/27\">",
"      Miyazaki E, Miyazaki M, Chen JM, et al. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/28\">",
"      Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/29\">",
"      Gillespie SH, Gosling RD, Uiso L, et al. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005; 56:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/30\">",
"      Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/31\">",
"      Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008; 52:4037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/32\">",
"      Bozeman L, Burman W, Metchock B, et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/33\">",
"      Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007; 167:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/34\">",
"      Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/35\">",
"      Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/36\">",
"      Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/37\">",
"      Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. J Antimicrob Chemother 1999; 43 Suppl B:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/38\">",
"      Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/39\">",
"      von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci. J Antimicrob Chemother 1996; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/40\">",
"      Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/41\">",
"      Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988; 32:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/42\">",
"      Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994; 38:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/43\">",
"      Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/44\">",
"      Snydman DR, Jacobus NV, McDermott LA, et al. In vitro activities of newer quinolones against bacteroides group organisms. Antimicrob Agents Chemother 2002; 46:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/45\">",
"      Mant TG. Multiple-dose pharmacokinetics of lomefloxacin: rationale for once-a-day dosing. Am J Med 1992; 92:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/46\">",
"      Lode H, H&ouml;ffken G, Boeckk M, et al. Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother 1990; 26 Suppl B:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/47\">",
"      Nightingale CH. Overview of the pharmacokinetics of fleroxacin. Am J Med 1993; 94:38S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/48\">",
"      Flor S. Pharmacokinetics of ofloxacin. An overview. Am J Med 1989; 87:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/49\">",
"      Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997; 41:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/50\">",
"      S&ouml;rgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition. Am J Med 1993; 94:44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/51\">",
"      Staib AH, Beermann D, Harder S, et al. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am J Med 1989; 87:66S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/52\">",
"      Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 1996; 40:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/53\">",
"      Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 1996; 37 Suppl A:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/54\">",
"      Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/55\">",
"      Allen A, Bygate E, Vousden M, et al. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother 2001; 45:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/56\">",
"      Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/57\">",
"      Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl B:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/58\">",
"      S&ouml;rgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. Am J Med 1993; 94:56S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/59\">",
"      Outman WR, Nightingale CH. Metabolism and the fluoroquinolones. Am J Med 1989; 87:37S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/60\">",
"      Efthymiopoulos C, Bramer SL, Maroli A, Gambertoglio JG. Effect of renal impairment on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997; 33 Suppl 1:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/61\">",
"      Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother 1994; 38:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/62\">",
"      Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/63\">",
"      Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 2004; 54:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/64\">",
"      Fillastre JP, Leroy A, Moulin B, et al. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother 1990; 26 Suppl B:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/65\">",
"      Montay G, Gaillot J. Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 1990; 26 Suppl B:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/66\">",
"      Berkovitch M, Pastuszak A, Gazarian M, et al. Safety of the new quinolones in pregnancy. Obstet Gynecol 1994; 84:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/67\">",
"      Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/68\">",
"      Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/69\">",
"      Schaad UB, abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/70\">",
"      Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/71\">",
"      Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21:407.",
"     </a>",
"    </li>",
"    <li>",
"     Glaxo withdraws Raxar following seven fatal cardiovascular AEs. \"The Pink Sheet\", November 1, 1999, p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/73\">",
"      McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/74\">",
"      Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABAA receptors by 4-quinolones. J Antimicrob Chemother 1993; 31:457.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. Risk of fluoroquinolone-associated myasthenia gravis exacerbation &mdash;  February 2011 label changes for fluoroquinolones. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm247115.htm (Accessed on March 16, 2011).",
"    </li>",
"    <li>",
"     Avelox (moxifloxacin hydrochloride) tablet and injection. Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; August 2012. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm319318.htm (Accessed on January 23, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/77\">",
"      Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/78\">",
"      Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990; 26 Suppl D:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/79\">",
"      Rizk E. The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. Am J Med 1992; 92:130S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/80\">",
"      Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37 Suppl A:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/81\">",
"      Ferguson J. Fluoroquinolone photosensitization: A review of clinical and laboratory studies. Photochem Photobiol 1995; 62:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/82\">",
"      Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 Suppl 2:S144.",
"     </a>",
"    </li>",
"    <li>",
"     Avelox (moxifloxacin hydrochloride) prescribing information. Bayer HealthCare Pharmaceuticals, Inc. Wayne, NJ. file://www.avelox.com/html/pdf/avelox_prescribing.pdf (Accessed on November 05, 2009).",
"    </li>",
"    <li>",
"     Levaquin (levofloxacin) prescribing information. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Raritan, NJ. file://www.levaquin.com/levaquin/shared/pi/levaquin.pdf#zoom=100 (Accessed on November 05, 2009).",
"    </li>",
"    <li>",
"     Cipro (ciprofloxacin hydrochloride) prescribing information. Bayer HealthCare Pharmaceuticals, Inc. Wayne, NJ. file://www.univgraph.com/bayer/inserts/ciprotab.pdf (Accessed on November 05, 2009).",
"    </li>",
"    <li>",
"     Noroxin (norfloxacin) prescribing information. Merck &amp; Co, Inc. Whitehouse Station, NJ. file://www.merck.com/product/usa/pi_circulars/n/noroxin/noroxin_pi.pdf (Accessed on November 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/87\">",
"      Adam D. Use of quinolones in pediatric patients. Rev Infect Dis 1989; 11 Suppl 5:S1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/88\">",
"      Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 1992; 30:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/89\">",
"      Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/90\">",
"      van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/91\">",
"      van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/92\">",
"      Melhus A, Apelqvist J, Larsson J, Eneroth M. Levofloxacin-associated Achilles tendon rupture and tendinopathy. Scand J Infect Dis 2003; 35:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/93\">",
"      Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36:1404.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121598.htm (Accessed on April 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/95\">",
"      Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012; 125:1228.e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/96\">",
"      Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/97\">",
"      Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/98\">",
"      Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000; 45:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/99\">",
"      Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003; 23:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/100\">",
"      Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996; 37 Suppl A:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/101\">",
"      Lapi F, Wilchesky M, Kezouh A, et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012; 55:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/102\">",
"      Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.",
"     </a>",
"    </li>",
"    <li>",
"     Factive (gemifloxacin mesylate) prescribing information. Oscient Pharmaceuticals. Waltham, MA. file://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=6881 (Accessed on November 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/104\">",
"      Paterson JM, Mamdani MM, Manno M, et al. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012; 184:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/105\">",
"      Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/106\">",
"      Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9:517.",
"     </a>",
"    </li>",
"    <li>",
"     Bristol Tequin labeling update includes new indication, glucose warning. In: \"The Pink Sheet\" vol. 64 no. 43. F-D-C Reports, Inc. Chevy Chase, Maryland 2002. p.14.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/108\">",
"      Hypoglycemia and hyperglycemia with fluroroquinolones. Med Lett Drugs Ther 2003; 45:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/109\">",
"      Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005; 41:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/110\">",
"      Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/111\">",
"      Aspinall SL, Good CB, Jiang R, et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009; 49:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/112\">",
"      Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/113\">",
"      Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992; 14:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/114\">",
"      Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989; 33:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/115\">",
"      Robson RA. The effects of quinolones on xanthine pharmacokinetics. Am J Med 1992; 92:22S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/116\">",
"      Stahlmann R, Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother 1997; 40 Suppl A:83.",
"     </a>",
"    </li>",
"    <li>",
"     Hori S, Shimada S. Effects of quinolones on the central nervous system. In: Quinolone antimicrobial agents, 2nd ed, Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC 1993. p.513.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/60/28618/abstract/118\">",
"      Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996; 22:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 490 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28618=[""].join("\n");
var outline_f27_60_28618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H527964309\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology of resistant strains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Conventional bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Newer quinolones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gram-negative organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Respiratory pathogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gram-positive organisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drug concentrations in serum and other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Half-lives of the drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Routes of elimination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Renal clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hepatic and biliary excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dose adjustments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Use in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Rash and other allergic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      QT interval prolongation and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Transaminitis and liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hypoglycemia and hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H142842158\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H527964309\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/1/20509\" title=\"table 1A\">",
"      Quinolone MICs versus GNR I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/0/26637\" title=\"table 1B\">",
"      Quinolone MICs versus GNR II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19245\" title=\"table 2\">",
"      Quinolone MICs vs GPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/3/4157\" title=\"table 3\">",
"      Quinolone MIC anaer myco",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/3/41020\" title=\"table 4\">",
"      Pharmacokinetics of quinolones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 5\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/490|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 1A\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 1B\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32537?source=related_link\">",
"      Achilles tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_60_28619="Risk factors for growth impairment in pediatric CKD";
var content_f27_60_28619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for growth impairment in children with chronic kidney disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Genetic factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parent height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Syndromal disorder (with CKD as part of the syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age at start of CKD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of CKD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residual renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment modalities for CKD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Energy malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water and electrolyte disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hormonal disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disturbance of parathyroid hormone and vitamin D (renal osteodystrophy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disturbance of the somatotropic hormonal axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disturbance of the gonadotropic hormonal axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disturbance of insulin/glucose metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disturbance of other hormones",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CKD: chronic kidney disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28619=[""].join("\n");
var outline_f27_60_28619=null;
var title_f27_60_28620="Risk factors for SIDS";
var content_f27_60_28620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiologic risk factors for SIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        General factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low birth weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Racial/ethnic differences (increased risk in nonwhite races)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender - male greater than female",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Climate - twofold increased risk in cold versus warm months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Maternal and antenatal factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking, illicit drugs&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Young, unmarried, no high school degree&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late or no prenatal care&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor gestational weight gain&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy complications (placenta previa, abruption, premature rupture of membranes)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection, sexually transmitted disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short interpregnancy interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neonatal factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prematurity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small for gestational age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vital signs -",
"        <strong>",
"         not",
"        </strong>",
"        a risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea of prematurity -",
"        <strong>",
"         not",
"        </strong>",
"        a risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Post neonatal factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prone sleep position - 1.3-fold increased risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep environment - soft sleep surfaces, loose bedding accessories, bed-sharing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent gastrointestinal illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listlessness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast feeding -&nbsp;",
"        <strong>",
"         reduces",
"        </strong>",
"        risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent upper respiratory infection -",
"        <strong>",
"         not",
"        </strong>",
"        a risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunizations -",
"        <strong>",
"         not",
"        </strong>",
"        a risk",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SIDS: sudden infant death syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hoffman HJ, Damus K, Hillman L, Krongrad E. Risk factors for SIDS. Results of the National Institute of Child Health and Human Development SIDS Cooperative Epidemiological Study. Ann N Y Acad Sci 1988; 533:13.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28620=[""].join("\n");
var outline_f27_60_28620=null;
var title_f27_60_28621="Causes HTN children";
var content_f27_60_28621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of secondary hypertension in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Renal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyelonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal parenchymal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital anomalies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reflux nephropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute glomerulonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Henoch-Sch&ouml;nlein purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydronephrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemolytic uremic syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal stones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrotic syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wilm's tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypoplastic kidney",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polycystic kidney disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital adrenal hyperplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cushing syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary aldosteronism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary hyperparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pheochromocytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased intracranial pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Guillain-Barr&eacute; syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Psychologic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mental stress",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pharmacologic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sympathomimetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stimulants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anabolic steroids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phencyclidine (PCP)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Licorice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal artery abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal vein thrombosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coarctation of the aorta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Patent ductus arteriosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arteriovenous fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heavy metal poisoning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Collagen vascular diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibromatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberous sclerosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <br>",
"       <ol>",
"        <li>",
"         Tunnessen WW, Roberts, KB. Hypertension. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.413.",
"        </li>",
"        <li>",
"         Pappadis SL, Somers MJ. Hypertension in adolescents: a review of diagnosis and management. Curr Opin Pediatr 2003; 15:370.",
"        </li>",
"       </ol>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28621=[""].join("\n");
var outline_f27_60_28621=null;
var title_f27_60_28622="Electrical axis of ECG leads";
var content_f27_60_28622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrical axis of ECG leads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The frontal plane (extremity or limb) ECG leads are represented on a hexaxial diagram. Each lead has a specific spatial orientation and polarity. The positive pole of each lead axis (red, solid line) and negative pole (blue, solid line) are designated by their angular position relative to the positive pole of lead I (0&deg;). The QRS axis, which is normally between -30&deg; and +100&deg;, can be estimated as being at right angles to the positive pole of any extremity lead in which the positive and negative deflections are of roughly equal magnitude.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28622=[""].join("\n");
var outline_f27_60_28622=null;
var title_f27_60_28623="Deep hemangioma";
var content_f27_60_28623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deep hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep hemangiomas are typically raised, flesh-colored nodules, which often have a bluish hue or an overlying telangiectatic patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_60_28623=[""].join("\n");
var outline_f27_60_28623=null;
